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ABSTRACT 
Fanconi anemia (FA) is a rare autosomal and X-linked recessive disorder, 
characterized by congenital abnormalities, pediatric bone marrow failure and cancer 
susceptibility. FA is caused by biallelic mutations in any one of 16 genes. The FA 
proteins function cooperatively in the FA-BRCA pathway to repair DNA interstrand 
crosslinks (ICLs). The monoubiquitination of FANCD2 and FANCI is a central step in 
the activation of the FA-BRCA pathway and is required for targeting these proteins to 
chromatin. Despite their critical role in ICL repair, very little is known about the 
structure, function, and regulation of the FANCD2 and FANCI proteins, or how they 
are targeted to the nucleus and chromatin. The goal of this dissertation is to study the 
mechanisms and regulation of FANCD2. Through this research, we have uncovered a 
nuclear localization signal (NLS) in FANCD2. Mutation of this NLS region impairs 
FANCD2 and FANCI monoubiquitination and inhibits the recruitment of FANCD2 
and FANCI to chromatin. In addition, we have identified a putative CDK 
phosphorylation site cluster in FANCD2. Taken together, we believe these findings 
have enhanced our understanding of this important DNA repair protein and will allow 
for further investigation of this rare cancer susceptibility syndrome. 
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PREFACE 
The following dissertation has been prepared in manuscript format. Chapter 1, 
“The Fanconi Anemia ID2 Complex: Dueling Saxes at the Crossroads”, was published 
in Cell Cycle and is a review encompassing our current understanding of the 
regulation and function of the FANCD2 and FANCI proteins. Chapter 2, “Coordinate 
Nuclear Targeting of the FANCD2 and FANCI Proteins via a FANCD2 Nuclear 
Localization Signal” was published in PLoS One. Chapter 3, “Characterization of a 
Putative CDK Phosphorylation Site Cluster in the FANCD2 Protein” was prepared for 
submission to PLoS Genetics. 
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Fanconi anemia (FA) is a rare recessive genetic disease characterized by 
congenital abnormalities, bone marrow failure and heightened cancer 
susceptibility in early adulthood. FA is caused by biallelic germ-line mutation of 
any one of 16 genes. While several functions for the FA proteins have been 
ascribed, the prevailing hypothesis is that the FA proteins function cooperatively 
in the FA-BRCA pathway to repair damaged DNA. A pivotal step in the 
activation of the FA-BRCA pathway is the monoubiquitination of the FANCD2 
and FANCI proteins. Despite their importance for DNA repair, the domain 
structure, regulation, and function of FANCD2 and FANCI remain poorly 
understood. In this review, we provide an overview of our current understanding 
of FANCD2 and FANCI, with an emphasis on their posttranslational 
modification and common and unique functions. 
 
The Discovery of FANCD2 and FANCI 
FANCD2  
The FANCD2 gene was identified in 2001 by the Grompe, D‟Andrea, and Moses 
Laboratories using a positional gene cloning approach, following many years of 
collaborative efforts.
1-4
 The PD20 FA patient line was originally assigned to the FA-D 
complementation group because of its inability to complement the mitomycin C 
(MMC) hypersensitivity of the FA-D reference line HSC62.
4-6
 Using a microcell-
mediated chromosome transfer approach, the FANCD gene was initially mapped to 
3p22-26.
4
 Hejna and colleagues subsequently narrowed the critical region to ~200 kb, 
a region which harbored three candidate genes: TIGR-A004X28, SGC34603, and 
 4 
 
AA609512.
2
 Timmers and colleagues then used rapid amplification of cDNA ends 
(RACE) to obtain the respective full-length cDNAs and sequenced these three genes 
in the PD20 cells.
1
 No sequence changes were uncovered in A004X28 and AA609512. 
However, five sequence changes were found in SGC34603; three of which represented 
common polymorphisms and two represented bona fide mutations. One sequence 
alteration was a maternally inherited A to G transition at nucleotide 376, which 
resulted in a S to G missense change. This transition was also associated with 
missplicing and insertion of 13 nt from intron 5 into the mRNA, causing a frameshift 
and production of a severely truncated protein. A second paternally inherited sequence 
change in SGC34603 resulted in an R to H missense and hypomorphic change at 
position 1236 (R1236H),
1
 strongly suggesting that SGC34603 was indeed the FANCD 
gene. Confirming this, transduction of PD20 cells with full-length wild-type FANCD 
rescued the MMC hypersensitivity of these cells.
1
 No sequence changes in SGC34603 
however were uncovered in HSC62. These findings led to the delineation of two FA-D 
complementation groups, FA-D1 and FA-D2, with biallelic mutations in 
SGC34603/FANCD2 causative for the FA-D2 complementation group.
1
 Early 
biochemical studies of the FANCD2 protein uncovered two isoforms: an unmodified 
form and a higher molecular mass isoform posttranslationally modified through the 
covalent attachment of a single ubiquitin polypeptide, referred to as 
monoubiquitination.
3
 
 
FANCI  
The existence of the FA-I complementation group was first established by Levitus and 
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colleagues, on the basis of somatic cell hybrid complementation analyses,
7
 and the 
FANCI gene was subsequently identified by three groups in 2007.
8-10
 Using a two-step 
genome-wide linkage approach with four genetically informative families, Dorsman 
and colleagues identified four candidate regions encompassing 39.4 Mb and 
comprising 351 genes. The sequencing of several candidate DNA repair genes failed 
to reveal sequence alterations. However, two strong alternative candidate genes - 
KIAA1794/NP_060663 and C15orf42/NP_689472 - were interrogated due to their 
resemblance to known FA genes in their extent of evolutionary conservation and the 
presence of nuclear localization signals, as many FA proteins, including FANCD2, 
were known to be nuclear.
3, 11-14
 Sequencing of the KIAA1794 gene in all eight FA-I 
patients uncovered pathogenic mutations.
8
  
Employing a phosphoproteomics screen to identify substrates of the DNA 
damage response kinases ATM (ataxia-telangiectasia mutated) and ATR (ATM and 
Rad3-related), the Elledge group identified KIAA1794 as an ionizing radiation-
inducible phosphoprotein.
15
 An amino acid sequence alignment of KIAA1794/FANCI 
and FANCD2 uncovered a modest overall 13% identity and 20% primary sequence 
similarity. However, a higher degree of sequence conservation was revealed in the 
region encompassing KIAA1794/FANCI K523 and that flanking FANCD2 K561, the 
site of FANCD2 monoubiquitination.
3, 10
 Subsequent experiments established that, like 
FANCD2, FANCI is monoubiquitinated following treatment of cells with DNA 
damaging agents and during S phase of the cell cycle.
10
 While full-length 
KIAA1794/FANCI protein was detected by immunoblotting in BD0952, an Epstein-
Barr virus-transformed lymphocyte line from an FA patient of unassigned 
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complementation group, monoubiquitinated FANCI was not detected in these cells. 
DNA sequencing revealed homozygosity for two base substitutions in 
KIAA1794/FANCI in BD0952 cells. These included a C to T transition leading to a 
P55L amino acid change, and a G to A transversion leading to a R1285Q change, the 
latter representing the pathogenic mutation.
10
 
In an alternative strategy, Sims and colleagues performed a BLAST search 
using the conserved amino acid sequence flanking the site of FANCD2 
monoubiquitination K561, LVIRK, to identify proteins with similar 
monoubiquitination „consensus‟ sequences.9 A highly similar sequence - LVLRK - 
was uncovered in the uncharacterized protein KIAA1794, which, upon further 
examination, displayed approximately 40% sequence similarity within the regions 
surrounding KIAA1794 K523 and FANCD2 K561.
9
 KIAA1794/FANCI was shown to 
undergo DNA damage-inducible monoubiquitination, and, importantly, this 
monoubiquitination was dependent on both the presence and monoubiquitination of 
FANCD2.
9
 Sims and colleagues subsequently sequenced all of the exons and intron-
exon boundaries of the FANCI gene for several FA patients of unassigned 
complementation group with defective FANCD2 monoubiquitination. Biallelic 
mutations in FANCI were uncovered in four patients. Patient EUFA592 expressed an 
amino-terminal truncated FANCI as a result of a homozygous T to A transition in 
exon 2 leading to the creation of a cryptic start site at M94.
9
 Patient F010191 was 
compound heterozygous for FANCI mutations, with one allele encoding a R614X 
variant and the other encoding FANCI R1299X. Only the latter variant was detectable 
by immunoblotting. F010191 cells were defective for both FANCI and FANCD2 
 7 
 
monoubiquitination indicating an important role for the extreme carboxy-terminus of 
FANCI in the regulation of this posttranslational modification. Importantly, all FA-I 
patients examined expressed some FANCI protein suggesting that FANCI null 
mutations may lead to embryonic lethality.
9
    
 
FA-D2 and FA-I Clinical Aspects 
FA is a clinically heterogeneous disease characterized by a wide spectrum of 
congenital abnormalities, a predisposition to develop early-onset progressive bone 
marrow failure (BMF), and an increased risk of developing solid tumors in early 
adulthood. The carrier frequency of FA was previously estimated at 1:300 with an 
expected incidence rate of approximately 1:360,000.
16
 However, a more recent report 
cites a higher carrier frequency of 1:156 - 1:209, leading to an expected incidence rate 
of 1:130,000.
17
 A much higher carrier frequency of approximately 1:100 is found in 
certain populations, including Spanish Romani, Ashkenazi Jews, and Afrikaaners; this 
increase being attributed to the founder effect.
17
 
 It had previously been estimated that the FA-D2 complementation group 
accounts for ~1-3% of all FA patients.
18, 19
 However, more recently it has been 
reported that this complementation group accounts for approximately 6% of all FA 
patients.
20
 Patients belonging to the FA-D2 complementation group display the 
common FA congenital malformations including skin hypo- or hyper-pigmentation, 
short stature, and microcephaly (Table 1).
20-22
 Importantly, these physical 
abnormalities, along with skeletal irregularities such as radial ray deformities, often 
allow for early clinical diagnosis. One notable difference between the FA-D2  
 8 
 
 9 
 
complementation group and others is the penetrance of congenital abnormalities: 
while it is estimated that ~30% of individuals with FA do not display any congenital 
abnormality, every FA-D2 patient in one study exhibited a congenital defect.
20
 
Distinct phenotypes have also been observed in Fancd2 knockout mice that are not 
observed in Fanca, Fancc, or Fancg mutant mice. 
23
 Houghtaling and colleagues 
discovered that Fancd2-/- mice have a high prevalence of micropthalmia, an increased 
incidence of epithelial tumors, severe hypogonadism, as well as perinatal lethality.
23
  
In addition to the congenital abnormalities, an earlier mean age of onset of BMF is 
observed for FA-D2 patients, compared to patients from all other FA complementation 
groups - 4.5 y compared to 8.0 y.
20, 24
 Similar to that mentioned above for FA-I 
patients, residual FANCD2 protein expression is detected in the vast majority of FA-
D2 patient cells, suggesting that only hypomorphic FANCD2 mutations are compatible 
with viability. The majority of FANCD2 mutations detected among FA-D2 patients 
are homozygous missense or compound heterozygous for a missense mutation and 
nucleotide change affecting splicing, often leading to monoallelic expression of low 
levels of both non- and monoubiquitinated FANCD2.
1, 20
  
 To date, only 12 patients from the FA-I complementation group have been 
described, compared to 30 FA-D2 patients. Much less is known about FA-I patients‟ 
clinical manifestations, and this complementation group only accounts for an 
estimated less than 1% of all FA cases.
18
 Of the few FA-I patients with available 
clinical data, all have growth retardation (Table 2).
8, 9
 In addition, approximately 50% 
of FA-I patients exhibit radial ray defects as well as both kidney and heart anomalies. 
Furthermore, the age of onset of hematological manifestations among FA-I patients  
 10 
 
 11 
 
varies widely, ranging from 1 - 8 y, and the average age of onset of BMF for the small 
number of FA-I patients documented is 5.4 y.
8
 Of the limited FA-I population size 
examined to date, to our knowledge no unique clinical manifestations have been 
observed. 
 
Domain Architecture and Structure of FANCD2 and FANCI 
FANCD2 is a 1,451 amino acid protein with a molecular mass of 164 kDa. When 
originally identified, FANCD2 was described as an orphan protein, as no recognizable 
domains or enzymatic motifs were evident.
1
 To date, only four FANCD2 
domains/motifs have been experimentally characterized (Figure 1A). The carboxy-
terminal EDGE motif, named for the single letter amino acid code, is not required for 
FANCD2 monoubiquitination or nuclear foci formation. However, this motif is 
necessary for complementation of the ICL-sensitivity of FA-D2 patient cells.
25
 An 
interaction between FANCD2 and the major DNA processivity factor PCNA has also 
been described.
26
 FANCD2 contains a highly conserved PIP-motif (PCNA-interacting 
protein motif) which is necessary for the association of FANCD2 with PCNA 
(proliferating cell nuclear antigen), and for efficient FANCD2 monoubiquitination, 
nuclear foci formation and ICL repair, suggesting that PCNA may function as a 
molecular scaffold to facilitate FANCD2 function.
26
 FANCD2 also harbors an amino-
terminal CUE (coupling of ubiquitin conjugation to endoplasmic reticulum 
degradation) ubiquitin-binding domain (UBD).
27
 The CUE domain adopts a triple -
helical configuration and mediates noncovalent ubiquitin binding. The CUE domain is 
important for interaction with FANCI, for the retention of monoubiquitinated  
 12 
 
Figure 1. Domain architecture and structure of FANCD2 and FANCI. (A) 
Schematic of the FANCD2 protein indicating the amino-terminal NLS (nuclear 
localization signal) domain (green), CUE (coupling of ubiquitin conjugation to 
endoplasmic reticulum degradation) domain (maroon), PIP-box (PCNA-interacting 
protein motif) (orange), and the carboxy-terminal EDGE motif (purple). Functionally-
characterized phosphorylation sites (teal) and K561 monoubiquitination site (yellow) 
are indicated by small circles. (B) Schematic of the FANCI protein indicating the Leu 
(leucine zipper) domain (light blue), ARM (armadillo repeat) domain (pink), and 
carboxy-terminal EDGE motif (purple) and NLS domain (green). The S/TQ motif 
(teal) and K523 site of monoubiquitination (yellow) are indicated by small circles. (C) 
Mouse Fanci-Fancd2 heterodimer crystal structure represented as both surface and 
ribbons with domains indicated. This structure was solved by the Pavletich group in 
2011(PDB ID: 3S4W).
35
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FANCD2 and FANCI in chromatin, and for efficient ICL repair.
27
 In addition, the 
amino terminal 58 amino acids of FANCD2 harbors a nuclear localization signal 
(NLS).
28
 This sequence is required for the efficient nuclear localization of both 
FANCD2 and FANCI, and for their monoubiquitination and function in ICL repair.
28
 
 FANCI is a 1,328 amino acid protein with a molecular mass of 149 kDa 
(Figure 1B). FANCI has an armadillo (ARM) repeat domain, which form superhelical 
folds involved in mediating protein-protein interactions.
10, 29
 FANCI also possesses an 
amino-terminal leucine zipper domain, a domain capable of mediating protein-protein 
or DNA-protein interactions.
30, 31
 The FANCI leucine zipper domain does not bind 
directly to DNA, but does contribute to FANCI protein stability.
31
 The conserved 
carboxy-terminus of FANCI includes a putative EDGE motif and NLS, which have 
been shown to enhance DNA binding and to promote the nuclear localization of 
FANCI, respectively.
31, 32
 FANCI also possesses numerous S/TQ motifs, known 
ATM/ATR phosphorylation consensus sites, and mass spectrometry revealed that at 
least five of these sites are phosphorylated in human and mouse FANCI.
 15, 33, 34
 The 
alignment of human and chicken FANCI sequences revealed that eight S/TQ motifs 
are highly conserved, with six of these motifs clustering proximal to K523, the site of 
FANCI monoubiquitination.
9, 10, 33
 
  Importantly, the 3.4Å crystal structure of the murine Fancd2-Fanci heterodimer 
(ID2) was recently solved by the Pavletich laboratory. While this structure continues 
to be a major resource for FA researchers, it is important to recognize that structural 
information remains lacking for several peptide stretches of both proteins.
35
 Fancd2 
and Fanci are structurally highly similar and consist largely of antiparallel -helices 
 15 
 
that form -superhelical structures referred to as solenoids. Fancd2 and Fanci fold 
into back-to-back, inverted saxophone-like structures with trough-like partially open 
ends (Figure 1C). Multiple positively charged grooves within these troughs are 
capable of accommodating single and double-stranded DNA. The sites of 
monoubiquitination are located in the ID2 interface within solvent accessible tunnels. 
However, these tunnels are predicted to be too small to accommodate the ubiquitin 
ligase machinery, raising challenging questions about the temporal, kinetic, and spatial 
aspects of FANCD2 and FANCI monoubiquitination.
35
 
 
FANCD2 and FANCI Monoubiquitination  
Protein ubiquitination is a multi-step post-translational modification that results in the 
covalent attachment of a single ubiquitin molecule (monoubiquitination) or chain of 
linked ubiquitin molecules (polyubiquitination) to a lysine residue on a substrate 
protein. Mono- and poly-ubiquitination signal a wide range of cellular instructions, the 
former being most typically associated with the targeting of proteins to specific sub-
cellular localizations, while the canonical role of the latter is to target proteins for 
degradation by the proteasome.
36, 37
 In the general process of ubiquitination, an E1 
ubiquitin-activating enzyme activates ubiquitin by forming a thioester bond between a 
catalytic C of E1 and the carboxy-terminal G76 of ubiquitin. Ubiquitin is then 
transferred from the E1 to an active site C of an E2 ubiquitin-conjugating enzyme. 
Ubiquitin can be further transferred to the catalytic site of a HECT (homologous to 
E6-AP carboxy terminus) domain-containing E3 ubiquitin ligase, and then 
subsequently transferred to a target K on the substrate. Alternatively, through the 
 16 
 
action of a RING (really interesting new gene) domain-containing E3 ubiquitin ligase, 
ubiquitin is transferred directly from the E2 to the substrate. The human genome 
encodes two E1 ubiquitin-activating enzymes, ~40 E2 ubiquitin-conjugating enzymes, 
and >600 E3 ubiquitin ligases.
38
  
 As mentioned above, when the FANCD2 protein was first characterized by 
Garcia-Higuera and colleagues in 2001, two isoforms of FANCD2 were detected by 
immunoblotting; a short form approximately 164 kDa and a longer form 
approximately 173 kDa.
3
 The latter isoform was determined to represent FANCD2 
covalently linked to a single ubiquitin polypeptide on K561.
3
 Similar to FANCD2, a 
slower migrating isoform of FANCI was also detected by immunoblotting, following 
treatment of cells with DNA damaging agents.
9
 This slower migrating FANCI isoform 
was subsequently determined to represent FANCI monoubiquitinated on K523.
9, 10
 
The monoubiquitination of FANCD2 and FANCI is required for their assembly into 
discrete nuclear foci, where they co-localize with several proteins including the 
protein product of one of the major breast and ovarian cancer susceptibility genes 
BRCA1.
3, 9, 10
 This seminal finding provided an important clue as to a potential 
function for FANCD2, FANCI, and the FA-BRCA pathway, as BRCA1 had 
previously been determined to play a key role in DNA repair by homologous 
recombination (HR).
39-41
 HR is an error-free and conservative DNA repair pathway 
that utilizes an intact homologous template, such as a sister chromatid or homologous 
chromosome, to repair DNA damage.
42
 The ability of FANCD2 and FANCI to 
promote error-free HR repair was assessed using the DR-GFP HR reporter assay 
system developed by the Jasin laboratory.
43, 44
 This reporter assay comprises two 
 17 
 
differentially mutated nonfunctional GFP genes oriented in tandem, and separated by 
a drug selection marker. One GFP gene is interrupted with the rare 18-bp I-Sce I 
restriction endonuclease recognition sequence, while the other is an 812-bp internal 
fragment. Following induction of a DSB with the I-Sce I endonuclease, a gene 
conversion HR event results in the expression of GFP, which can be assayed by flow 
cytometry or fluorescence microscopy.
43
 Knockdown of either FANCD2 or FANCI, 
as well as mutation of FANCD2 K561 or FANCI K523, which precludes the covalent 
attachment of ubiquitin, leads to decreased HR efficiency.
9, 10, 44
 Taken together, this 
data strongly suggests that monoubiquitinated FANCI and FANCD2 function 
cooperatively to promote error-free HR repair. Importantly, FANCD2 and FANCI 
monoubiquitination and nuclear foci formation are interdependent.
9, 10
 For example, 
siRNA-mediated depletion of FANCI results in decreased FANCD2 
monoubiquitination and nuclear foci formation, as well as a reduction in steady state 
levels of FANCD2.
9, 10
 These findings were suggestive of a physical interaction 
between FANCD2 and FANCI, and indeed this was verified by co-
immunoprecipitation studies as well as by co-crystallization of the murine ID2 
heterodimer.
10, 35
 Mutation of FANCD2 K561 renders this protein incompetent for 
nuclear foci formation, and abrogates its ability to rescue the ICL hypersensitivity of 
FA-D2 patient cells. Mutation of FANCI K523 also precludes its assembly into 
nuclear foci.
9, 10
 However, somewhat surprisingly, in contrast to FANCD2 K561, 
mutation of FANCI K523 does not overtly affect its function in ICL repair.
3, 9, 10, 33
 In 
vitro studies have also revealed that mutation of FANCD2 K561 leads to impaired 
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FANCI monoubiquitination, whereas mutation of FANCI K523 has little effect on the 
monoubiquitination of FANCD2.
45
 
The E2 ubiquitin-conjugating enzyme and E3 ubiquitin ligase for FANCD2 
and FANCI monoubiquitination are UBE2T and the RING domain-containing 
FANCL, respectively.
46, 47
 Biallelic mutations in the FANCL gene underlie the FA-L 
complementation group, however, FA patient-derived mutations in UBE2T have yet to 
be uncovered.
46, 47
 In addition to UBE2T and FANCL, the monoubiquitination of 
FANCD2 and FANCI requires the assembly of the FA core complex, comprising 
FANCA, FANCB, FANCC, FANCE, FANCF, FANCG, and FANCM, as well as 
numerous accessory proteins including FAAP20, FAAP24, FAAP100, MHF1, and 
MHF2.
48-53
 The precise roles of these ancillary proteins in FANCD2/FANCI 
monoubiquitination remain to be determined. Indeed, in vitro FANCD2/FANCI 
monoubiquitination reactions have been reconstituted with FANCL in the absence of 
these FA core complex components.
54-56
 Recent studies have identified three 
functional modules within the FA core complex: the FANCB-FANCL-FAAP100 
module, which provides the critical catalytic activity, and the FANCA-FANCG-
FAAP20 and FANCC-FANCE-FANCF modules, which independently promote the 
recruitment of the core complex to chromatin.
57, 58
 Accordingly, using isogenic single 
and double mutants of the HCT116 colorectal carcinoma cell line, Huang et al. 
established that FANCD2/I monoubiquitination is completely abrogated in the absence 
of FANCB, FANCL, or FAAP100, and only partially abrogated in the absence of 
FANCA, FANCG, FANCE, or FAAP20.
57
 Furthermore, in contrast to FANCD2, the 
purified FA core complex fails to robustly promote the monoubiquitination of FANCI 
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in the absence or presence of DNA.
58
 To gain further insight into the relationship 
between the FA core complex members and FANCD2/I monoubiquitination, it is 
useful to draw comparisons with other large multi-subunit ubiquitin ligase protein 
complexes, such as the Skp1/Cullin/F-box protein complex (SCF) (Figure 2).
59
 SCF, 
along with the anaphase-promoting complex or cyclosome (APC/C), plays an intricate 
and critical role in cell-cycle regulation.
60
 The F-box protein of the SCF complex 
functions in substrate recognition and recruitment.
59
 A good candidate for an FA-
pathway protein analogous to the SCF F-box protein is FANCE, a FA core complex 
member that has been demonstrated to interact with FANCC, FANCF, and FANCD2, 
thereby bridging the core ubiquitin ligase machinery and the substrate.
61
 The FANCE-
FAND2 interaction, via FANCE F522, is critical for efficient FANCD2 
monoubiquitination and ICL repair.
62
 The Cullin protein functions as a molecular 
scaffold for the SCF complex, bridging the catalytic RING finger subunit RBX1 to the 
adaptor and F-box proteins. The FANCA protein, with a molecular mass of 163 kDa, 
may play a similar structural role in the FA-BRCA pathway. FANCA interacts with 
FANCC, FANCG, and FAAP20.
12, 57, 58, 63, 64
 The Skp1 protein of the SCF complex 
functions as an adaptor between the Cullin protein and the F-box protein.
65
 FANCC 
interacts with FANCA, FANCE, and FANCF and thus represents a strong candidate 
Skp1 analog.
57, 58, 61
 FANCM is present in very low abundance in the native FA core 
complex, consistent with its role in replication fork remodeling and chromatin loading 
of the core complex.
58, 66-68
 The core complex members FANCM, FANCG, and 
FANCF do not appear to have analogous SCF components. FANCL is analogous to 
the SCF E3 ubiquitin ligase RBX1. As mentioned above, FANCL, FANCB, and  
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Figure 2. Comparison of the SCF multi-subunit ubiquitin ligase protein complex 
and the FA core complex. (A) The Skp1/Cullin/F-box protein (SCF) complex 
includes the Cullin protein, which acts as a scaffold to bridge the catalytic E3 ubiquitin 
ligase RBX1 to the adaptor protein Skp1, and the F-box protein.
59
 The F-box protein 
recognizes and recruits the target protein for ubiquitination by the E2 ubiquitin-
conjugating enzyme, UBC. (B) We propose that the FANCA protein is structurally 
analogous to Cullin, and may link the E3 ubiquitin ligase FANCL with the putative 
adaptor protein FANCC. FANCC has been shown to interact with both FANCA and 
FANCE, indicating that it may function analogously to Skp1.
61
 FANCE may be 
analogous to the F-box protein. FANCE is known to interact directly with FANCD2 
and may facilitate its monoubiquitination of FANCL and UBE2T.
62
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FAAP100 comprise the E3 monoubiquitin ligase catalytic module.
57, 58
 
FANCL and RBX1 are both RING E3 ubiquitin ligases, with the RING domain 
facilitating recruitment of the E2 ubiquitin-conjugating enzyme, UBE2T in the case of 
the FA-BRCA pathway and UBC3, UBC4, or UBC5 for SCF.
46, 65, 69
 FANCL binds to 
FANCD2 via its DRWD domain, and to UBE2T via its RING domain, to facilitate 
monoubiquitination.
69, 70
 
 
Ubiquitination: Mono- versus Poly- 
To date, only the monoubiquitination of FANCD2 has been observed, begging the 
question; how is monoubiquitinated FANCD2 restricted from being 
polyubiquitinated? Insights into this question can be gained from extensive studies of 
regulators of endocytosis. Many endocytic proteins are monoubiquitinated in a process 
referred to as coupled monoubiquitination, whereby substrate recognition and 
ubiquitination are regulated, at least in part, through noncovalent interactions between 
ubiquitin and substrate ubiquitin-binding domains (UBDs). One such example is 
EPS15 (epidermal growth factor receptor pathway substrate 15), an important 
regulator of the endocytosis of ligand-inducible receptors of the receptor tyrosine 
kinase (RTK) family, in particular EGFR.
71
 EPS15 is monoubiquitinated by the 
NEDD4 HECT E3 ubiquitin ligase and by the Parkin RING E3 ubiquitin ligase. 
EPS15 harbors two ubiquitin-interacting motifs (UIMs) in its carboxy-terminus that 
are critical for its regulation. One proposed model for why EPS15 is solely 
monoubiquitinated is that once ubiquitinated, EPS15 undergoes an intramolecular 
rearrangement enabling covalently attached ubiquitin to engage in a noncovalent 
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interaction with one of its two carboxy-terminal UIMs, generating a closed 
conformation refractory to further ubiquitination.
72, 73
 The crystal structure of the 
murine ID2 heterodimer has revealed that the mouse Fancd2 K559 and Fanci K522 
sites of monoubiquitination are buried within the ID2 interface. A solvent accessible 
tunnel adjacent to these sites is predicted to be too small to accommodate UBE2T, 
suggesting that monoubiquitination either precedes heterodimerization or occurs 
subsequent to ID2 dissociation. Similar to the EPS15 UIM, one possibility is that ID2 
heterodimerization occurs following monoubiquitination, and that the ID2 heterodimer 
is stabilized through a noncovalent interaction between monoubiquitin covalently 
linked to FANCI K523 and the FANCD2 CUE domain, and quite possibly a reciprocal 
interaction between monoubiquitinated FANCD2 K561 and an UBD in the carboxy-
terminus of FANCI (Figure 3A).
27
 Thus, FANCD2 and FANCI might be shielded 
from further ubiquitination via intermolecular association. It is also possible that 
monoubiquitination promotes an intramolecular association between ubiquitin 
covalently attached to K561 and the amino-terminal CUE domain,
27
 potentially 
blocking the ubiquitin on K561 from further ubiquitination, similar to that for EPS15 
(Figure 3B). The latter model would more closely align with recent findings from the 
Sobeck laboratory indicating that activation of the FA-BRCA pathway coincides with 
dissociation of FANCD2 and FANCI.
74
 ID2 dissociation is triggered by ATM/ATR-
mediated phosphorylation of a cluster of at least six FANCI SQ/TQ motifs, and is 
followed by the monoubiquitination of FANCD2, see below.
33, 74
  
The NEDD4 E3 ubiquitin ligase can mono- and polyubiquitinate substrates, 
and the balance between these two posttranslational modifications is determined, at  
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Figure 3. Models for FANCD2 and FANCI monoubiquitination. The schematics 
depict several potential outcomes upon monoubiquitination of FANCD2 and FANCI, 
which would preclude further ubiquitination. (A) The ID2 heterodimer inactivation 
model. Following monoubiquitination, ID2 heterodimerization occurs and is stabilized 
through a noncovalent interaction between monoubiquitin covalently linked to FANCI 
K523 and the FANCD2 CUE domain. There is also possibly a reciprocal interaction 
between monoubiquitinated FANCD2 K561 and an UBD in the carboxy-terminus of 
FANCI, shielding FANCD2 from further ubiquitination. (B) The FANCD2 self-
inactivation model. Monoubiquitination could promote an intramolecular association 
between ubiquitin covalently attached to K561 and the amino-terminal CUE domain, 
resulting in a closed conformation. (C) The E3 ubiquitin ligase dissociation model. 
Once FANCL is autoubiquitinated, the ubiquitin moiety may interact noncovalently 
with the CUE domain on FANCD2 enabling monoubiquitination of FANCD2 on 
K561. This interaction is predicted to be weak and short-lived, leading to rapid 
dissociation of FANCL and FANCD2, precluding further ubiquitination. 
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least in part, by the nature of the enzyme-substrate interaction. The tryptophan-
tryptophan (WW) motif of NEDD4 can interact with relatively high affinity to a 
substrate PPxY (where x is any amino acid) motif, leading to substrate 
polyubiquitination.
75, 76
 EPS15 lacks a PPxY motif and instead interacts with NEDD4 
via a weak noncovalent interaction between ubiquitin covalently conjugated to 
NEDD4 and one of its carboxy-terminal UIMs.
77, 78
 Similarly, EPS15 interacts with 
the Parkin RING E3 ubiquitin ligase via a weak interaction between an ubiquitin-like 
domain (UbL) in Parkin and one of its UIMs.
79
 Previous studies have indicated that 
the FANCL E3 ubiquitin ligase, as well as the UBE2T E2 ubiquitin-conjugating 
enzyme, undergoes autoubiquitination.
54, 80
 Therefore, the FANCD2 CUE domain may 
interact with ubiquitin conjugated to FANCL (or UBE2T) and, because of the weak 
nature of this interaction, FANCD2 and FANCL may rapidly dissociate following 
ubiquitination, precluding further ubiquitination (Figure 3C).   
 Another major factor influencing mono- versus poly-ubiquitination is the 
nature of the E2 ubiquitin-conjugating enzyme. There are ~40 E2 ubiquitin-
conjugating enzymes encoded by the human genome, 28 of which are classified as 
monoubiquitinating E2s. The FANCD2/I E2 ubiquitin-conjugating enzyme UBE2T is 
classified as a monoubiquitinating E2.
46, 54, 56, 80
 Several other E2s function as 
polyubiquitinating E2s and display ubiquitin linkage-specificity. For example, 
UBE2G1, UBE2G2, UBE2K, UBE2R1, and UBE2R2 promote the assembly of K48-
linked polyubiquitin chains, while UBE2S and UBE2N promote the assembly of K11- 
and K63-linked polyubiquitin chains, respectively.
81
  In the case of UBE2N, K63-
linked polyubiquitin chain assembly is facilitated by the cofactor proteins UBE2V1 
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and UBE2V2, which structurally align K63 of the acceptor ubiquitin toward the active 
site C of UBE2N.
82, 83
 Thus, the monoubiquitination fate of FANCD2 and FANCI may 
simply be determined by the mechanistic nature of UBE2T. Nevertheless, much 
remains to be learned about the mechanism, structure, and regulation of UBE2T.   
 Lastly, the concentration of an E3 ubiquitin ligase relative to the concentration 
of its substrate has also been shown to play an important role in determining if a 
protein is monoubiquitinated or polyubiquitinated. One example of this mechanism of 
regulation applies to the ubiquitination of the p53 tumor suppressor protein by its E3 
ubiquitin ligase MDM2: When levels of MDM2 are low, p53 is largely 
monoubiquitinated. Conversely, when levels of MDM2 are high, p53 is predominantly 
polyubiquitinated.
84
 Likewise, it is plausible that the cellular concentration of FANCL 
is sufficient for FANCD2/I monoubiquitination only, precluding further 
ubiquitination.  
 
FANCD2 and FANCI Deubiquitination 
The site-specific monoubiquitination of FANCD2 and FANCI is a reversible process. 
The deubiquitination of monoubiquitinated FANCD2 and FANCI is mediated by 
ubiquitin-specific protease 1 (USP1). This important function for USP1 was 
uncovered in a DUB (deubiquitinating enzyme) gene family RNA interference library 
screen, whereby knockdown of USP1 resulted in a significant increase in 
monoubiquitinated FANCD2.
85
 Deletion of murine Usp1 results in increased perinatal 
lethality, male infertility, and an FA phenotype.
86
 Usp1-/- mouse embryonic fibroblasts 
(MEFs) exhibit elevated levels of Fancd2 monoubiquitination and impaired Fancd2 
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nuclear foci formation and are defective in HR repair.
86
 USP1 is activated upon 
formation of a complex with the UAF1 (USP1 associated factor-1) protein.
87
 The 
amino-terminus of UAF1 has a WD40 domain, which binds and activates USP1, while 
the carboxy-terminus contains two SUMO-like domains (SLD1 and SLD2) that 
mediate substrate binding.
87, 88
 FANCI harbors a highly conserved SUMO-like 
domain-interacting motif (SLIM) that has been shown to interact with SLD2 of UAF1, 
targeting USP1/UAF1 to the ID2 complex.
88
 USP1/UAF1 activity is tightly regulated: 
upon exposure to UV irradiation, USP1 undergoes inhibitory autocleavage.
89
 The 
carboxy-terminal fragment of autocleaved USP1 is subsequently degraded by the R/N-
end rule pathway, leading to the effective elimination of deubiquitinating activity.
90
 
The USP1 gene is also transcriptionally repressed upon cellular exposure to DNA 
damaging agents, a process that requires the function of the p21 cyclin-dependent 
kinase inhibitor.
87, 91
 Both negative regulatory mechanisms facilitate the timely 
accumulation of monoubiquitinated FANCD2 and FANCI following the induction of 
DNA damage.
89 
 
FANCD2 Phosphorylation 
The FANCD2 protein is also subject to posttranslational modification by 
phosphorylation. The ATM kinase is a member of the phosphatidylinositol-3-OH-
kinase-like family of protein kinases (PIKK). Bilallelic mutations in the ATM gene 
cause the autosomal recessive disorder Ataxia- telangiectasia (AT).
92
 AT is clinically 
characterized by progressive cerebellar ataxia, telangiectasias, immune defects, and 
increased susceptibility to hematologic cancers of B and T cell origin, as well as 
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central nervous system tumors.
93, 94
 The ATM kinase plays a major coordinating role 
in the cellular response to DNA DSBs and phosphorylates multiple substrates to halt 
cell cycle progression and initiate DNA repair. For example, the ATM kinase 
phosphorylates T68 of the CHK2 kinase following exposure to ionizing radiation (IR) 
to initiate cell cycle arrest at the G1-S boundary.
95
 In 2002, Taniguchi and colleagues 
discovered that ATM phosphorylates FANCD2 on S222, S1401, S1404, and S1418 in 
response to IR exposure.
96
 Phosphorylation of FANCD2 S222 is required for the 
establishment of the IR-inducible S phase checkpoint, an ability to pause DNA 
synthesis in the presence of chromosomal DSBs.
97
 However, ATM-mediated 
FANCD2 S222 phosphorylation is dispensable for FANCD2 monoubiquitination, 
nuclear foci formation, and ICL resistance.
96
  
An important role for the ATR kinase in the regulation of FANCD2 has also 
been established.
98, 99
 While ATM primarily responds to DNA DSBs, ATR is a major 
regulator of the DNA replication checkpoint, primarily responding to agents that 
disrupt DNA replication, e.g. hydroxyurea, an inhibitor of deoxyribonucleotide 
reductase, aphidicolin (APH), a processive DNA polymerase inhibitor, and UV 
irradiation, which promotes the formation of cyclobutane pyrimidine dimers.
100, 101
 
Mutations in ATR underlie Seckel syndrome (SCKL1) a rare autosomal recessive 
disorder characterized by severe growth retardation, short stature, microcephaly, 
mental retardation, and increased risk for acute myeloid leukemia (AML), 
myelodysplasia (MDS), and aplastic anemia, similar to FA.
102-104
 Following exposure 
to DNA crosslinking agents, ATR and FANCD2 co-localize in nuclear foci.
98, 105
 ATR 
also promotes efficient DNA damage-inducible FANCD2 monoubiquitination and 
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nuclear foci formation.
98
 Accordingly, similar to FA patient cells, ATR-deficient 
SCKL1 patient cells exhibit increased chromosome aberrations, including radial 
formations, following exposure to MMC.
98, 104
 The D‟Andrea laboratory established 
that ATR phosphorylates FANCD2 on T691 and S717 in vitro and in vivo.
98, 99
 A 
FANCD2-T691A/S717A double mutant fails to undergo efficient DNA damage-
inducible monoubiquitination and fails to correct the MMC hypersensitivity of FA-D2 
patient cells.
99
 How phosphorylation of these two sites promotes FANCD2 
monoubiquitination remains unclear. Phosphorylated T691 and S717 may stimulate 
interaction with the core complex or with FANCL or UBE2T, promoting 
monoubiquitination. Alternatively, phosphorylation may promote dissociation from 
FANCI, allowing access to K561, similar to that described for FANCI, see below. 
Phosphorylation could also promote the interaction of FANCD2 with DNA in 
chromatin, which has been shown to lead to increased efficiency of 
monoubiquitination.
56, 106
  
 
FANCI Phosphorylation 
FANCI was originally identified as an ATM/ATR substrate in a large-scale SILAC 
(stable isotope labeling with amino acids in cell culture) proteomics screen.
15
 As 
described above, six S/TQ motifs are positioned proximal to K523, the sites of 
monoubiquitination. These S/TQ sites become phosphorylated in the absence of prior 
monoubiquitination, indicating that this posttranslational modification acts upstream 
of monoubiquitination.
33
 Importantly, mutation of these S/TQ sites results in 
abrogation of FANCI and FANCD2 monoubiquitination and nuclear foci formation,
33
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indicating that phosphorylation of the FANCI S/TQ cluster functions as a molecular 
switch to activate the FA-BRCA pathway. However, the underlying molecular 
mechanism remains unclear. Recently, it has been suggested that activation of the 
pathway coincides with disassociation of the ID2 heterodimer, and that ID2 
disassociation is triggered by ATM/ATR-mediated phosphorylation of the S/TQ 
cluster.
106
 Using cell-free Xenopus laevis egg extracts, Sareen and colleagues 
demonstrated that a FANCI S/TQ cluster phosphorylation-dead mutant failed to 
dissociate from FANCD2 and failed to undergo monoubiquitination. Conversely, a 
phosphorylation-mimetic mutant failed to associate with FANCD2 and exhibited 
increased monoubiquitination.
106
 Taken together, these findings indicate that 
phosphorylation of FANCI at the conserved S/TQ cluster is a key mechanism in the 
activation of the FA-BRCA pathway. The introduction of a cluster of negatively 
charged phosphate groups may result in a localized charge repulsion that promotes 
ID2 disassociation, enabling access of the previously occluded ubiquitin ligase 
machinery. 
 
FANCD2 and FANCI Function 
Replisome Surveillance 
Early studies indicated that, in addition to being monoubiquitinated following 
exposure to DNA damaging agents, FANCD2 and FANCI monoubiquitination also 
occurs during unperturbed cell cycle progression. In addition, monoubiquitinated 
FANCD2 co-localizes with BRCA1 and RAD51 in nuclear foci during S phase.
97
 
These findings strongly suggested that monoubiquitinated FANCD2 might play an 
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important role in maintaining genome stability during the process of DNA 
replication.
10, 97
 Accordingly, the FANCD2 and FANCA proteins are required for the 
maintenance of common chromosomal fragile site (CFS) stability.
107
 CFS are 
chromosomal loci that are prone to breakage when cells are cultured under conditions 
of DNA replication stress, for example following treatment with low concentrations of 
the DNA polymerase inhibitor APH.
108
 CFSs are hot spots for sister chromatid 
exchanges (SCE), chromosomal translocations, and viral integration, and are 
frequently rearranged or deleted in cancer.
109
 The physical localization of FANCD2 
and FANCI to FRA3B and FRA16D, the most frequently expressed CFSs, has also 
been demonstrated.
110
 Combined immunofluorescence microscopy and FISH analysis 
of metaphase chromosomes revealed the presence of paired FANCD2/I-stained CFSs 
on sister chromatids linked by BLM helicase-associated ultra-fine DNA bridges 
(UFBs).
110, 111
 These paired FANCD2/I sister foci form during S phase and persist into 
mitosis, and their presence strongly suggest that FANCD2 and FANCI participate in 
the resolution of stalled or collapsed DNA replication forks that recurrently arise at 
particularly unstable genomic loci.
107, 110, 111
 In further support of an important role for 
FANCD2 in the resolution of stalled or collapsed replication forks, Fancd2-/- MEFs 
are ICL hypersensitive yet do not display increased sensitivity to IR.
23
 Consistent with 
a role for the FA-BRCA pathway in the DNA replication stress response, FANCD2 
has been shown to interact with several components of the DNA replisome. For 
example, as mentioned earlier, FANCD2 interacts with the DNA polymerase 
processivity factor PCNA, via a conserved PIP-box, and this interaction is necessary 
for efficient FANCD2 monoubiquitination and ICL repair.
26
 In addition, using a 
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method called iPOND (isolation of proteins on nascent DNA), the Cortez group 
recently discovered that FANCD2 and FANCI, in addition to ATR, MRE11 and other 
proteins, are highly enriched at stalled and collapsed replication forks following 
depletion of deoxyribonucleotide pools.
112
 Interestingly, FANCI, and not FANCD2, 
was also shown to accumulate at active replication forks prior to fork staling, 
suggesting common and independent functions for these proteins. 
112
 In addition, the 
Vaziri group has recently shown that FANCD2 is necessary for efficient initiation of 
DNA replication in primary human fibroblasts.
113
 An unbiased proteomics screen of 
chromatin-bound FANCD2 immune complexes revealed that FANCD2 physically 
associates with the minichromosome maintenance 2-7 (MCM2-MCM7) replicative 
helicases.
114, 115
 FANCD2 interacts with MCM2-MCM7 in response to ATR-mediated 
DNA replication stress signaling independently of the core FA complex and 
monoubiquitination.
115
 In the absence of FANCD2, replication forks stall 
stochastically and primary cells exhibit increased senescence, indicating that FANCD2 
is required for replication fork progression.
115
 Schlacher and colleagues also showed 
that FANCD2 is necessary to protect stalled replication forks from MRE11-mediated 
degradation, and that fork protection in the absence of FANCD2 can be rescued by 
RAD51.
116
 Moreover, it was recently discovered that FANCD2, in cooperation with 
BRCA1 and MRE11, recruits and interacts with CtIP (CtBP-interacting protein) at 
stalled replication forks to promote replication restart.
117, 118
 CtIP was originally 
identified on the basis of its ability to bind to CtBP (C-terminal binding protein), a 
transcriptional co-repressor.
118
 However, several recent studies have established that 
CtIP interacts with the MRN (MRE11/RAD50/NBS1) complex and BRCA1 and 
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facilitates the DNA strand resection step of HR repair.
118-121
 This evidence supports a 
key role for FANCD2 and FANCI in coordinating the recruitment of HR proteins to 
sites of stalled replication forks, enabling timely replication fork resolution and 
progression. 
 In addition to being directly regulated by the FANCL-UBE2T ubiquitin ligase 
machinery, several studies have established that FANCD2/I monoubiquitination is 
indirectly regulated by the RAD18-RAD6 E3/E2-ubiquitin ligase complex.
122-126
 
RAD18-RAD6 catalyzes the monoubiquitination of PCNA on K164, a molecular 
event necessary for DNA polymerase switching during translesion DNA synthesis 
(TLS).
127, 128
 TLS polymerases possess larger active sites and exhibit reduced fidelity, 
and have the ability to catalyze DNA polymerization opposite DNA templates 
harboring aberrantly modified nucleobases.
129
 RAD18 and FANCD2, as well as 
FANCL, function epistatically in the cellular ICL response.
122, 126
 Genetic disruption 
of RAD18 or RAD18 depletion via siRNA leads to decreased ICL-induced FANCD2/I 
monoubiquitination and chromatin binding.
122-126
 Furthermore, RAD18-RAD6 
mediated monoubiquitination of PCNA on K164 is necessary for efficient FANCD2 
monoubiquitination.
122
 FANCL was also shown to bind to PCNA directly and PCNA 
K164 monoubiquitination was shown to be required for FANCL chromatin loading.
122
 
While the molecular mechanism underlying this regulation remains unclear, these 
findings suggest that the FANCL-UBE2T and RAD18-RAD6 ubiquitin ligases 
cooperatively regulate FANCD2/I and PCNA monoubiquitination, respectively, to 
facilitate the coordinated recruitment of HR and TLS factors to stalled or collapsed 
replication forks.  
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Independent Functions of FANCD2 and FANCI 
BLM Complex Chromatin Assembly 
Since the discovery of FANCI, it has generally been accepted that FANCD2 and 
FANCI function cooperatively in the resolution of ICLs. However, several recent 
studies have suggested independent functions for these proteins. For example, it has 
recently been determined that FANCD2, and not FANCI, is an important regulator of 
the recruitment of the BLM helicase to chromatin.
130
 Biallelic mutations in the BLM 
gene underlie Bloom syndrome (BS), a rare recessive disorder characterized by growth 
retardation, sunlight sensitivity, telangiectasia, hypo- or hyper-pigmentation of the 
skin, and increased susceptibility to hematologic cancers.
131
 The BLM helicase is a 
member of the RecQ family of helicases, which also includes the WRN and RECQ4 
proteins, and possesses ATP-dependent 3‟-5‟ DNA helicase activity.132 Similar to FA 
patient cells, BS patient cells are hypersensitive to the cytotoxic effects of DNA 
crosslinking agents as well as agents that inhibit DNA replication.
133, 134
 In addition, 
FANCD2 and BLM co-localize in nuclear foci following exposure to DNA damaging 
agents.
134
 Pichierri and colleagues established that the DNA damage-inducible 
phosphorylation of BLM and its ability to assemble into nuclear foci are compromised 
in FA-C and FA-G patient cells.
134
 In contrast, FANCD2 monoubiquitination and 
nuclear foci formation, as well as the DNA damage-inducible chromatin localization 
of FANCA and FANCC, are intact in BS patient cells.
134
 Similarly, using Xenopus egg 
extracts, Chaudhury et al recently showed that immunodepletion of both FANCD2 
and FANCI leads to a failure of the BLM helicase, and its binding partners TOP3a, 
RMI1, RM2, and RPA1-3, to associate with chromatin. Notably, FANCD2 alone is 
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sufficient to rescue this defect.
130
 Furthermore, neither FANCI nor FANCD2 
monoubiquitination are required to promote BLM complex chromatin assembly, 
indicating that this function is monoubiquitination and FANCI-independent.
130
 
  
Nucleosome Assembly Activity 
FANCD2 was recently identified in a proteomics screen of histone H3/H4-interacting 
proteins.
135
 Recombinant FANCD2 was subsequently confirmed to bind to H3/H4 in 
vitro.
135
 These findings suggested that FANCD2 might play an active role in 
chromatin dynamics and/or reorganization. Indeed, using a topological assay and a 
nucleosome assembly assay, FANCD2 was shown to promote nucleosome assembly 
to an extent comparable to that of the known nucleosome assembly protein Nap1. 
Similar to the promotion of BLM complex chromatin localization, FANCD2 histone 
binding and nucleosome assembly activity appear to be FANCI and 
monoubiquitination-independent.
135
 However, while FANCI fails to promote 
nucleosome assembly by itself, it can stimulate FANCD2-mediated nucleosome 
assembly at low FANCD2 concentrations. These results suggest that the ID2 complex 
may promote chromatin reorganization during ICL repair. Consistent with this 
hypothesis, FANCD2 was previously discovered to interact with the 60 kDa Tat-
interactive protein (TIP60) chromatin remodeling acetyltransferase and menin, a 
chromatin remodeling tumor suppressor.
136, 137
 Depletion of TIP60 using siRNA 
sensitizes cells to ICL cytotoxicity.
137
 TIP60 is a subunit of the NuA4 chromatin 
remodeling complex, which comprises multiple enzymatic subunits including TIP60, 
the p400 motor ATPase, and the RUVBL1 and RUVBL2 helicase-like proteins.
138
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Upon DSB generation, TIP60 is rapidly recruited to sites of damage where it 
acetylates multiple substrates including H2A, H4, p53, and ATM.
139-142
 Menin has 
also been shown to function in chromatin remodeling, and DNA repair.
136, 143, 144
 Cells 
lacking menin are more sensitive to DNA damage and the interaction between 
FANCD2 and menin is increased following exposure to IR.
136
 Collectively, these 
findings suggest that FANCD2 may function in a chromatin remodeling capacity 
during the early stages of ICL repair. 
 
FANCD2: Recruitment of Nucleases 
Several recent studies have provided important mechanistic insight into the function of 
monoubiquitinated FANCD2 in ICL repair. The previously uncharacterized 
KIAA1018 protein was simultaneously identified by several groups as a FANCD2-
interacting partner and an important cellular determinant of ICL repair efficiency.
145-
147
 The Jiricny group identified KIAA1018 as a component of the mismatch repair 
MLH1 and PMS2 interactomes. This protein was predicted to harbor an amino-
terminal UBZ (ubiquitin-binding zinc finger) UBD and a carboxy-terminal PD-
D/E(X)K-type nuclease domain.
146
 Similarly, the Huang and Rouse groups identified 
KIAA1018 on the basis of its UBZ domain and a VRR_nuc (virus-type replication-
repair nuclease) domain, which contains a motif frequently found in bacterial and 
bacteriophage restriction nucleases.
145, 148
 Importantly, UBZ domains have been 
uncovered in several DNA damage response proteins, including RAD18 and DNA 
polymerase κ (POL κ).149, 150 In another approach, Smogorzewska and colleagues 
discovered KIAA1018 in an unbiased genome-wide shRNA screen of proteins 
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necessary for efficient ICL repair.
147
 KIAA1018 was found to co-localize with 
FANCD2 in nuclear foci following ICL exposure and to interact with FANCD2 via 
co-immunoprecipitation analysis, and was hence renamed FAN1 (FANCD2-
associated nuclease 1).
145-148
 FAN1 was shown to display 5‟-3‟ exonuclease activity 
and structure-specific endonuclease activity, preferentially toward 5‟ flap 
structures.
145-148
 Furthermore, the FAN1 UBZ domain was shown to interact 
noncovalently with monoubiquitin conjugated to FANCD2 K561. The FAN1 UBZ 
domain and the monoubiquitination of FANCD2 were shown to be required for the 
recruitment of FAN1 to sites of DNA damage, and for efficient ICL repair.
145
 While 
FAN1 mutations have yet to be uncovered in FA patients, mutations in FAN1 have 
been identified as a cause of karyomegalic interstitial nephritis, a chronic kidney 
disease.
151
  
Mutations in the SLX4 gene were recently uncovered in FA complementation 
group P.
152-154
 FANCP/SLX4 is a ~200 kDa multidomain protein that, similar to 
FAN1, harbors an amino-terminal UBZ domain.
155
 FANCP/SLX4 functions as a 
molecular platform to coordinate the activities of the structure-specific endonucleases 
XPF-ERCC1, MUS81-EME1, and SLX1, with XPF-ERCC1 playing a major role in 
ICL repair, and MUS81-EME1 and SLX1 playing less critical roles.
156-160
 Similar to 
FAN1 and FANCD2, FANCP/SLX4 and FANCD2 co-localize in nuclear foci and co-
immunoprecipitate.
154
 While Yamamoto and colleagues established that the 
FANCP/SLX4 UBZ domain and the monoubiquitination of FANCD2 are required for 
FANCP/SLX4 targeting to nuclear foci, a recent report has contradicted these findings 
and shown that SLX4 recruitment occurs independent of FANCD2 
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monoubiquitination.
154, 161
 Taken together, these findings suggest that one major 
function for chromatin-bound monoubiquitinated FANCD2 may be the recruitment of 
structure-specific endonucleases that mediate key incision steps during the process of 
ICL repair.
162
  
 
FANCD2 and FANCI: DNA Binding 
Several studies have established that FANCD2 and FANCI physically bind to DNA. 
Using FANCD2 purified from baculovirus-infected SF9 insect cells, the Parvin group 
originally determined that full-length FANCD2 binds to dsDNA and Holliday 
junctions (HJs), quadruplex heteroduplex DNA intermediates that arise during HR.
163
 
Similarly, the Zhang group purified full-length FANCI and demonstrated that it can 
bind to multiple DNA substrates, including HJs, dsDNA, ssDNA, and flap structures, 
without any apparent structural preference.
31
 Longerich et al also demonstrated that 
purified FANCI is capable of binding to dsDNA, ssDNA, and HJs.
80
 Importantly, 
however, co-purified ID2 displayed a much lower affinity for dsDNA and ssDNA, yet 
maintained a robust binding activity towards HJs and various branched DNA 
structures.
31
 Consistent with these findings, the Pavletich group described the structure 
of co-crystals of FANCI bound to splayed Y DNA at a resolution of 7.8 Å.
35
 Based on 
this structure and the structural homology between FANCD2 and FANCI, the authors 
proposed that the ID2 heterodimer could have two sets of pseudo-symmetrical 
dsDNA/ssDNA binding sites, structures that could arise upon stalling of one or two 
replication forks at an ICL.
35
 Notably, the Patel group discovered that, in addition to 
binding to dsDNA and ssDNA, FANCD2 exhibits 3‟ to 5‟ exonucleolytic activity 
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towards ssDNA in the presence of Mg
2+
 or Mn
2+
.
164
 However, the functional 
significance for this activity remains to be established. 
In addition, recent studies have established that FANCD2 monoubiquitination 
is strongly stimulated through DNA binding. For example, the Kurumizaka and Sung 
laboratories demonstrated that several forms of DNA, including dsDNA, ssDNA, and 
Holliday junctions, could robustly stimulate the in vitro monoubiquitination of 
FANCD2.
45, 56
 Of note, this DNA-dependent stimulation of FANCD2 
monoubiquitination required both the presence of FANCI and its ability to bind to 
DNA.
56
 Using Xenopus egg extracts, Sobeck and colleagues also demonstrated that the 
monoubiquitination of FANCD2 could be stimulated with linear and branched dsDNA 
structures but not with ssDNA or Y-shaped DNA.
165
  Expanding on these studies, the 
Sobeck group recently demonstrated that while FANCD2 monoubiquitination is 
strongly stimulated by circular and linear dsDNA, the monoubiquitination of FANCI 
is strongly stimulated by ssDNA and only weakly induced by circular and linear 
dsDNA, indicating a dichotomy in substrate specificity for both proteins.
74
 In addition, 
through a time course study, the same group determined that the monoubiquitination 
of FANCD2 in the presence of circular dsDNA and ssDNA occurs significantly earlier 
than the monoubiquitination of FANCI.
74
 FANCD2 was also found to localize to 
chromatin earlier than, and independent of, FANCI. In contrast, the localization of 
FANCI to chromatin is FANCD2-dependent.
74
   
Finally, recent studies from the D‟Andrea laboratory have established that 
FANCD2 promotes RAS oncogene-induced senescence in part by promoting the 
transcriptional activation of the TAp63 tumor suppressor gene.
166
 Monoubiquitinated 
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FANCD2 and FANCP/SLX4 bind to the TAp63 promoter and cooperate in the 
transcriptional activation of TAp63.
166
 Genome-wide ChIP sequencing (ChIP-seq) 
analysis revealed that following exposure to DNA damaging agents, FANCD2-Ub 
binds to cis-regulatory sequences of numerous genes essential for epithelial 
development and morphogenesis.
166
 This newly discovered function for FANCD2 in 
transcriptional regulation is supported by other studies describing the binding of 
FANCD2 to the TNF gene as well as the antioxidant genes GPX1 and TXNRD1, and 
constitutes a novel dimension to the portfolio of FANCD2 functions.
167, 168
 
 
Conclusions 
The FANCD2 and FANCI proteins function at a pivotal point in the FA-BRCA 
pathway and play an essential role in maintaining chromosome stability. Both proteins 
are critical for hematopoietic stem cell homeostasis and the prevention of cellular 
transformation. These key functions are achieved through what could be considered 
disparate means: the promotion of error-free HR repair through the recruitment of 
structure-specific endonucleases, replisome surveillance and resolution, nucleosome 
remodeling, as well as transcriptional regulation. However, these functions are not 
necessarily mutually exclusive and it is conceivable that FANCD2 and FANCI 
facilitate these processes through the recruitment of multiple binding partners and/or 
via a fundamental chromatin remodeling capacity. Many outstanding questions remain 
to be addressed, including 1) the identification and characterization of structural and 
functional domains of FANCD2 and FANCI, 2) cataloging the full spectrum and 
functional significance of additional FANCD2 and FANCI posttranslational 
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modifications, 3) identification of the FANCI catalytic ubiquitin ligase machinery, 4) 
determination of the function of monoubiquitinated FANCI (and FANCD2), and 5) 
elucidation of the roles of FANCB and FAAP100 in the regulation of FANCL activity. 
Much work remains to be done to clearly elucidate the structural and regulatory 
mechanisms of these functions. The achievement of these goals will no doubt greatly 
inform our understanding of the molecular etiology of FA and offer much needed 
direction in the urgent quest for potential therapeutics.  
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Abstract 
Fanconi anemia (FA) is a rare recessive disease, characterized by congenital defects, 
bone marrow failure, and increased cancer susceptibility. FA is caused by biallelic 
mutation of any one of sixteen genes. The protein products of these genes function 
cooperatively in the FA-BRCA pathway to repair DNA interstrand crosslinks (ICLs). 
A central step in the activation of this pathway is the monoubiquitination of the 
FANCD2 and FANCI proteins. Monoubiquitinated FANCD2 and FANCI localize to 
discrete chromatin regions where they function in ICL repair. Despite their critical role 
in ICL repair, very little is known about the structure, function, and regulation of the 
FANCD2 and FANCI proteins, or how they are targeted to the nucleus and chromatin. 
In this study, we describe the functional characterization of an amino-terminal 
FANCD2 nuclear localization signal (NLS). We demonstrate that the amino terminal 
58 amino acids of FANCD2 can promote the nuclear expression of GFP and is 
necessary for the nuclear localization of FANCD2. Importantly, mutation of this 
FANCD2 NLS reveals that intact FANCD2 is required for the nuclear localization of a 
subset of FANCI. In addition, the NLS is necessary for the efficient 
monoubiquitination of FANCD2 and FANCI and, consequently, for their localization 
to chromatin. As a result, FANCD2 NLS mutants fail to rescue the ICL sensitivity of 
FA-D2 patient cells. Our studies yield important insight into the domain structure of 
the poorly characterized FANCD2 protein, and reveal a previously unknown 
mechanism for the coordinate nuclear import of a subset of FANCD2 and FANCI, a 
key early step in the cellular ICL response. 
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Introduction 
Fanconi anemia (FA) is a rare autosomal and X-linked recessive disease, characterized 
by congenital abnormalities, pediatric bone marrow failure, and heightened cancer 
susceptibility [1].  FA is caused by biallelic mutations in any one of 16 genes 
(FANCA, -B, -C, -D1/BRCA2, -D2, -E, -F, -G, -I, -J/BRIP1, -L, -M, -N/PALB2, -
P/SLX4, O/RAD51C, Q/ERCC4) [2-4]. The protein products of these genes function 
cooperatively in the FA-BRCA pathway to repair DNA interstrand crosslinks (ICLs) 
and to maintain chromosome stability. A central step in the activation of the FA-
BRCA pathway is the monoubiquitination of the FANCD2 and FANCI proteins. 
Monoubiquitination of FANCD2 and FANCI is catalyzed by the FA core complex, 
which is comprised of FANCA, FANCB, FANCC, FANCE, FANCF, FANCG, 
FANCL, and FANCM, in addition to the E2 ubiquitin conjugating enzyme UBE2T, as 
well as FAAP100, FAAP24, and FAAP20 [4,5]. Following monoubiquitination, 
FANCD2 and FANCI co-localize in discrete nuclear foci with several well 
characterized DNA repair proteins including BRCA1 and NBS1 [6-9]. However, 
importantly, the domain structure, regulation, and function of both FANCD2 and 
FANCI are poorly described. Furthermore, the mechanism(s) by which FANCD2 and 
FANCI are localized to the nucleus remains unknown. 
Several studies have established that the FANCD2 and FANCI proteins 
function proximal to or within chromatin [6,8-10]. As FANCD2 and FANCI are 
relatively large proteins, with molecular weights of 164 and 149 kDa, respectively, the 
nuclear import of these proteins necessitates an energy-dependent active transport 
mechanism. The most common nuclear protein transport mechanism involves the 
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recognition of nuclear localization signals (NLSs) by members of the importin (Imp) 
superfamily of nuclear transporters, followed by translocation through the nuclear pore 
complexes [11]. NLSs generally comprise short stretches of basic amino acids either 
alone (monopartite) or separated by one (bipartite) or two (tripartite) mutation-tolerant 
linker regions of 10-12 amino acids (bipartite). NLSs in the cargo protein are 
recognized by the Imp α subunit of the Imp α/β heterodimer or by Imp β alone, and 
nuclear transport is coupled to GTP hydrolysis [11].   
In this study, we describe the identification and functional characterization of a 
NLS in the amino terminus of FANCD2. We demonstrate that the amino terminal 58 
amino acids of FANCD2 can promote the nuclear expression of green fluorescent 
protein (GFP). In addition, using deletion and site-directed mutagenesis strategies we 
establish that the amino terminal 58 amino acids of FANCD2 are necessary for the 
nuclear and chromatin localization of FANCD2 in FA-D2 patient-derived cells. 
Importantly, we also demonstrate that the nuclear and chromatin localization of a 
subset of the cellular pool of FANCI is dependent on the nuclear import of FANCD2. 
Moreover, the FANCD2 NLS is required for the efficient DNA damage-inducible 
monoubiquitination of FANCD2 and FANCI. Consequently, the FANCD2 NLS 
mutants fail to rescue the ICL hypersensitivity of FA-D2 patient-derived cells. Our 
results suggest that a subset of FANCI is translocated to the nucleus in a piggyback 
mechanism with FANCD2, dependent on its amino-terminal NLS, and suggest that 
FANCD2 and FANCI are targeted to the nucleus as a heterodimer. These findings 
lend important insight into the structure and regulation of two poorly characterized 
tumor suppressor proteins with key early roles in the cellular ICL response. 
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Results 
FANCD2 contains a highly conserved amino-terminal nuclear localization signal, 
which facilitates nuclear expression of GFP  
In silico analysis using cNLS mapper uncovered several high-scoring Imp α/-
dependent bipartite NLSs within the amino-terminal 58 amino acids of FANCD2 
(Figs. S1A and B) [12]. In contrast, cNLS mapper did not predict any high scoring 
NLSs in FANCI. A sequence alignment of FANCD2 from multiple species illustrates 
strong evolutionary conservation in general (Fig. S1C). However, in contrast to the 
sequence divergent carboxy-terminus, the alignment illustrates strong conservation of 
several blocks of basic amino acids within the amino terminal 58 amino acids (Figs. 
1A and S1C). To determine if this entire region or amino acids 1-27 or 24-58 - 
harboring the two highest scoring predicted NLSs - were sufficient for nuclear 
localization, we fused amino acids 1-58 (D2-1-58-GFP), 1-27 (D2-1-27-GFP), or 24-
58 (D2-24-58-GFP) of FANCD2 to the amino terminus of GFP (Fig. 1B). HeLa cells 
were transiently transfected with wild type GFP (GFP-WT) and the FANCD2-GFP 
fusion constructs and cells were analyzed by inverted fluorescence microscopy. HeLa 
cells transiently expressing GFP-WT, D2-1-27-GFP, or D2-24-58-GFP all exhibited 
uniform cytoplasmic and nuclear fluorescence (Fig. 1B). Conversely, cells transiently 
expressing D2-1-58-GFP primarily exhibited nuclear fluorescence (Fig. 1B). Similar 
findings were observed with IMR90 cells (Fig. S1D). These results demonstrate that 
the amino terminal 58 amino acids of FANCD2 are necessary to promote exclusive 
nuclear GFP localization. In support of an importin /-dependent mechanism of 
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Figure 1. The amino terminal 58 amino acids of FANCD2 contain a highly 
conserved nuclear localization signal, which facilitates nuclear expression of 
GFP. (A) A Clustal Omega multiple sequence alignment of the amino terminus of 
FANCD2 demonstrates strong evolutionary conservation of several blocks of basic 
amino acids of this region, indicated by blue bars. The red box indicates the highly 
conserved K4, R5, and R6 residues selected for mutagenesis. (B) The amino terminal 
58 amino acids of FANCD2 are required to promote exclusive nuclear expression of 
GFP. HeLa cells were transiently transfected with wild type GFP (GFP-WT), amino 
acids 1-27 (D2-1-27-GFP), 24-58 (D2-24-58-GFP), or 1-58 (D2-1-58-GFP) of 
FANCD2 fused to GFP followed by analysis by inverted fluorescence microscopy.  
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nuclear import, treatment with ivermectin, a broad-spectrum inhibitor of importin /-
dependent nuclear import [13], inhibited the exclusive nuclear localization of D2-1-
58-GFP, herein referred to as D2-NLS-GFP (Figs. S1E and F). In addition, mass 
spectrometry analysis of FANCD2 immune complexes revealed the presence of 
importin 1, as well as the nuclear pore complex proteins NUP160 and NUP155 
(Supplemental Table 1). Using a chromatin fractionation approach we also observed 
that the majority of GFP-WT resided in a soluble cytoplasmic and nuclear fraction (S) 
(Fig. S1G, lane 5). While a large proportion of D2-NLS-GFP also resided in a soluble 
cytoplasmic and nuclear fraction, a higher relative proportion of D2-NLS-GFP was 
detected in a chromatin-associated nuclear fraction (C) (Figs. S1G, lane 9 and H). 
Taken together these results demonstrate that the amino-terminal 58 amino acids of 
FANCD2 harbors a bona fide NLS that can promote exclusive nuclear GFP 
localization.  
  
The FANCD2 NLS is required for the nuclear localization of FANCD2 
To determine the functional significance of the FANCD2 NLS, we next generated 
deletion and missense mutations of this amino acid sequence. Two amino-terminal 
deletion mutations, FANCD2-N57, lacking amino acids 2-58, and FANCD2-N100, 
lacking amino acids 2-101, were generated (Fig. 2A). In addition, using a site-directed 
mutagenesis approach, amino acids K4, R5, and R6, the most highly conserved basic 
amino acids within this region (Fig. 1A), were mutated to N4, N5, and N6, herein 
referred to as FANCD2-3N (Fig. 2A). These FANCD2 cDNAs were cloned into the 
pLenti6.2 lentiviral vector, which contains a carboxy-terminal V5 tag, and lentivirus 
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Figure 2. The FANCD2 NLS is required for the nuclear localization of FANCD2. 
(A) Schematic diagram of the FANCD2 constructs generated in this study. In addition 
to the NLS, FANCD2 harbors a CUE (for coupling of ubiquitin conjugation to 
endoplasmic reticulum degradation) ubiquitin-binding domain [47], a PCNA-
interaction motif or PIP-box [19], and a carboxy-terminus EDGE motif [10]. (B) FA-
D2 cells stably expressing FANCD2-WT and FANCD2-∆N57 were incubated in the 
absence (NT) or presence of 40 nM MMC for 24 h. Cells were then incubated in the 
absence (-Pre-Perm) or presence (+Pre-Perm) of pre-permeablization buffer, fixed, 
stained with mouse monoclonal anti-V5 antibody (green) and counterstained with 
DAPI (blue). (C) FA-D2 cells stably expressing LacZ, FANCD2-WT, FANCD2-
∆N57, FANCD2-∆N100, and FANCD2-3N were incubated in the absence (NT) or 
presence of MMC for 24 h, fixed, and stained with rabbit polyclonal anti-FANCD2 
antibody, and counterstained with phalloidin and DAPI. At least 300 cells were scored 
for cytoplasmic (Cyto.), nuclear (Nucl.), and both cytoplasmic and nuclear (Both) 
localization of FANCD2.
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was used to generate a series of PD20 FA-D2 patient-derived cells stably expressing 
wild type or mutant FANCD2. These FA-D2 cells harbor a maternally inherited A-G 
change at nucleotide 376 that leads to the production of a severely truncated protein, 
and a paternally inherited missense hypomorphic mutation leading to a R1236H 
change [14]. Immunofluorescence microscopy (IF) revealed that deletion of the 
FANCD2 NLS resulted in exclusive cytoplasmic localization of FANCD2, in contrast 
to wild type FANCD2, which exhibited both diffuse and focal nuclear localization 
(Figs. 2B and C). Furthermore, permeabilization of FA-D2 cells expressing the 
FANCD2-N57 mutant with non-ionic detergent resulted in complete loss of 
fluorescent signal indicating the high solubility of cytoplasmic FANCD2-N57 (Fig. 
2B). In contrast, nuclear and focal localization of wild type FANCD2 was largely 
resistant to permeabilization (Fig. 2B). Similar findings were obtained with FA-D2 
cells expressing FANCD2-N100 (Fig. 2C). In addition, a partial yet significant 
defect in nuclear localization was observed for the FANCD2-3N mutant, compared to 
wild type FANCD2 (Fig. 2C).  
 
The FANCD2 NLS is required for the nuclear localization of a subset of FANCI 
Next, we examined the sub-cellular localization of FANCI in our FA-D2 cell series. It 
is important to note that the FA-D2 cells used in this study, like all known FA-D2 
patient-derived lines, harbor hypomorphic FANCD2 mutations and express residual 
FANCD2 protein [15]. IF analysis revealed that FANCI was uniformly present in both 
the cytoplasm and nucleus of FA-D2 cells in the absence or presence of MMC (Figs. 
3A and B). Importantly, complementation of FA-D2 cells with wild type FANCD2 
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Figure 3. The FANCD2 NLS is required for the nuclear localization of a subset of 
FANCI. (A) FA-D2 patient cells or FA-D2 cells stably expressing FANCD2-WT 
were incubated in the absence (NT) or presence of MMC for 24 h, fixed, stained with 
rabbit polyclonal anti-FANCD2 or anti-FANCI antibody and counterstained with 
phalloidin and DAPI. AF-488, Alexa Fluor 488. (B) FA-D2 cells stably expressing 
LacZ, FANCD2-WT, FANCD2-∆N57, FANCD2-∆N100, and FANCD2-3N were 
incubated in the absence (NT) or presence of MMC for 24 h, fixed, and stained with 
rabbit polyclonal anti-FANCI antibody, and counterstained with phalloidin and DAPI. 
At least 300 cells were scored for cytoplasmic (Cyto.), nuclear (Nucl.), and both 
cytoplasmic and nuclear (Both) localization of FANCI. (C) COS-7 cells were 
transiently transfected with no DNA, FANCI-GFP, FANCI-GFP plus FANCD2-V5-
WT, or FANCI-GFP plus FANCD2-V5-∆N57. Whole-cell lysates were 
immunoprecipitated with anti-V5 or anti-GFP antibodies and immune complexes 
immunoblotted with anti-GFP and anti-V5 antibodies.
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(FANCD2-WT) led to a large increase in exclusive nuclear localization of FANCI 
(Figs. 3A and B). Furthermore, MMC-inducible FANCI nuclear foci formation was 
restored in these cells, consistent with previous studies [8,9] (Fig. 3A). Similar results 
were obtained with hTERT-immortalized mutant and FANCD2-complemented KEAE 
FA-D2 patient-derived cells [15] (Fig. S2A). In contrast to wild type FANCD2, both 
the FANCD2-N57 and -N100 NLS mutants failed to promote the exclusive nuclear 
localization of FANCI (Figs. 3B and S2B). Furthermore, a partial defect in FANCI 
nuclear localization was observed for FA-D2 cells expressing FANCD2-3N (Fig. 3B). 
To rule out the possibility that deletion of the amino-terminus of FANCD2 prevented 
its heterodimerization with FANCI, we tested the ability of the FANCD2-N57 
mutant to physically interact with FANCI by transiently transfecting COS-7 cells with 
GFP-tagged FANCI and V5-tagged FANCD2-WT or FANCD2-N57 and examining 
their ability to interact by co-immunoprecipitation. Co-expression of both FANCD2-
WT and FANCD2-N57 with FANCI led to its stabilization (Fig. 3C, upper panel, 
lanes 3 and 4). Furthermore, the FANCD2-N57 mutant was capable of interacting 
with FANCI and, when corrected for levels of protein input, no appreciable difference 
in the level of interaction between FANCI and FANCD2-N57 and FANCI and 
FANCD2-WT was observed (Fig. 3C, lower panels, lanes 3 and 4). Together, these 
results establish that the nuclear localization of a subset of FANCI is dependent in part 
on FANCD2, and suggest a piggyback mechanism of nuclear FANCI targeting that is 
dependent on the FANCD2 amino-terminal NLS.  
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The FANCD2 NLS is required for efficient FANCD2 and FANCI 
monoubiquitination and chromatin association  
Next, we examined the consequences of disruption of the FANCD2 NLS on the 
monoubiquitination and chromatin localization of FANCD2 and FANCI. Similar to 
the FANCD2-K561R mutant that cannot be monoubiquitinated [6], mutation of the 
FANCD2 NLS had a significant impact on its monoubiquitination: the N57 and 
N100 NLS deletion mutants failed to undergo spontaneous or MMC-inducible 
FANCD2 monoubiquitination (Fig. 4A, lanes 7-10). A faint band of similar molecular 
weight to wild type FANCD2 can be seen in the -FANCD2 panel for FA-D2 cells 
expressing FANCD2-N57 and -N100 (Fig. 4A, lanes 7-10). This is most likely the 
hypomorphic FANCD2-R1236H missense mutant (see Materials and Methods) [14], 
as this band is also present in FA-D2 cells expressing LacZ (lanes 1 and 2) and is not 
recognized by the anti-V5 antibody (Fig. 4, lanes 7-10). The FANCD2-3N mutant 
also exhibited considerably reduced spontaneous and MMC-inducible 
monoubiquitination (Fig. 4A, lanes 11 and 12). Previous studies have demonstrated 
that FANCD2 and FANCI monoubiquitination are interdependent [8,9]. Accordingly, 
FANCI monoubiquitination was largely abrogated in FA-D2 cells stably expressing 
the N57 and N100 NLS deletion mutants, similar to that observed in cells 
expressing FANCD2-K561R (Fig. 4A, lanes 5-10). A very modest statistically 
insignificant decrease in FANCI monoubiquitination was also observed for FA-D2 
cells expressing the FANCD2-3N mutant (Fig. 4A, lanes 11 and 12). In addition, a 
chromatin fractionation approach revealed that the FANCD2-N57, -N100, and -3N 
mutants were largely defective in chromatin localization compared to FANCD2-WT  
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Figure 4. The FANCD2 NLS is required for efficient FANCD2 and FANCI 
monoubiquitination and chromatin association. (A) FA-D2 cells stably expressing 
LacZ, FANCD2-WT, FANCD2-K561R, FANCD2-∆N57, FANCD2-∆N100 and 
FANCD2-3N were incubated in the absence and presence of 250 nM MMC for 18 h, 
and whole-cell lysates were immunoblotted with antibodies to FANCD2, V5, FANCI 
and α-tubulin. The FANCD2 and FANCI L/S ratios are the ratios of 
monoubiquitinated to nonubiquitinated protein, and were calculated by measuring 
protein band intensities using ImageJ image processing and analysis software 
(http://rsb.info.nih.gov/ij/). (B and C) FA-D2 cells stably expressing FANCD2-WT, 
FANCD2-∆N57, FANCD2-∆N100 and FANCD2-3N were treated as above and cell 
pellets were fractionated into soluble (S) and chromatin-associated (C) fractions. 
Fractions were immunoblotted with antibodies against V5, FANCI, α-tubulin and 
H2A. W, unfractionated whole cell extract. 
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(Figs. 4B and C). Furthermore, while robust FANCI chromatin localization was 
observed for cells expressing FANCD2-WT, in comparison, FANCI chromatin 
localization was considerably diminished in cells expressing the FANCD2-N57, -
N100, and -3N mutants (Figs. 4B and C and S3). It is important to note that this 
particular fractionation protocol does not distinguish between true chromatin and the 
nuclear matrix.   
  
The FANCD2 NLS mutants fail to correct the ICL sensitivity of FA-D2 patient 
cells  
FA patient-derived cells are hypersensitive to ICL-induced cytotoxicity and 
clastogenicity [16]. Therefore, we next assessed the ability of the FANCD2 NLS 
mutants to rescue the MMC sensitivity of FA-D2 cells. In a MMC clastogenicity 
assay, FA-D2 cells expressing the N57 and N100 NLS mutants exhibited markedly 
elevated levels of chromosome aberrations, including gaps and breaks, dicentrics, and 
radial formations, compared with FA-D2 cells complemented with wild type FANCD2 
(p = 0.001 and 1.1 x 10
-5
, respectively for 16 nM MMC) (Fig. 5A). In addition, in a 
MMC cytotoxicity assay, similar to FA-D2 cells expressing FANCD2-K561R [6], 
cells expressing the FANCD2-N57 and -N100 NLS mutants displayed increased 
MMC sensitivity compared with cells expressing wild type FANCD2 (p < 0.05 at 50 
nM for FANCD2-N57, -N100, and -K561R compared with wild type FANCD2) 
(Fig. S4). Recent studies have demonstrated increased error-prone nonhomologous 
DNA end joining (NHEJ) in FA patient cells [17]. Therefore, we also examined the 
recruitment of DNA-PKCS to nuclear foci in FA-D2 cells expressing LacZ, wild type 
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Figure 5. The FANCD2 NLS mutants fail to correct the ICL sensitivity of FA-D2 
patient cells. (A) FA-D2 cells stably expressing LacZ, FANCD2-WT, FANCD2-
∆N57, FANCD2-∆N100, FANCD2-3N, or FANCD2-K561R were incubated in the 
absence or presence of 8 or 16 nM MMC for 24 h and the numbers of chromosome 
aberrations including gaps and breaks, dicentrics, and complex chromosome 
aberrations, including radial formations, were scored. Metaphase spreads were 
analyzed using a Zeiss AxioImager.A1 upright epifluorescent microscope with 
AxioVision LE 4.6 image acquisition software. At least 80 metaphases were scored 
per treatment. Error bars represent the standard error of the means. (B) FA-D2 cells 
stably expressing LacZ, FANCD2-WT and FANCD2-∆N57 were incubated in the 
absence (NT) or presence of 40 nM MMC for 18 h, and allowed to recover for 0, 4.5 
or 7 h. Cells were then fixed, stained with rabbit polyclonal anti-DNA-PKCS pS2056, 
and counterstained with DAPI. At least 300 cells were scored for nuclei with > 5 
DNA-PKCS foci. Error bars represent the standard error of the means from two 
independent experiments. ***, p < 0.001.
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FANCD2 or the FANCD2 N57 mutant, using an antibody raised against DNA-PKCS 
phosphorylated on S2056, a marker of NHEJ [17,18]. Persistent increased DNA-PKCS 
pS2056 nuclear foci formation was observed in FA-D2 cells expressing LacZ 
following treatment with MMC, and this phenotype was rescued by wild type 
FANCD2 (Fig. 5B). In contrast, we observed markedly increased MMC-inducible 
DNA-PKCS pS2056 nuclear foci formation in FA-D2 cells expressing FANCD2 N57, 
compared to cells expressing LacZ or wild type FANCD2 (Fig. 5B). Taken together, 
these results demonstrate that the FANCD2 NLS is essential for the correct function of 
the FA-BRCA pathway in the cellular ICL response. 
 
Discussion 
Despite their critical role in the cellular ICL response and their tumor suppressor 
function, very little is known about the structure, function, and regulation of the 
FANCD2 and FANCI proteins. For FANCD2, a large 1451 amino acid protein, only 
two functional motifs, a PCNA-interaction motif, or PIP box, and a carboxy-terminus 
EDGE motif, have been described to date [10,19]. Our laboratory has also recently 
identified and characterized a CUE ubiquitin-binding domain in the amino-terminus of 
FANCD2, which mediates noncovalent binding to ubiquitin, and is essential for 
efficient cellular ICL repair [20]. In this study we describe the functional 
characterization of an amino terminal FANCD2 NLS. While a previous study reported 
the existence of a FANCD2 NLS, this study failed to examine the functional 
consequences of its disruption in a FA-D2 patient-derived cell system [21]. Here, we 
demonstrate that fusion of amino acids 1-58 of FANCD2 to the amino terminus of 
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GFP drives its exclusive nuclear localization. cNLS mapper identified several high 
scoring putative bipartite NLSs within this region, in particular, amino acids 2-27 and 
24-55. However, in contrast to amino acids 1-58, fusion of either sequence to GFP 
failed to drive exclusive nuclear GFP expression. Furthermore, mutation of K4, R5, 
and R6, the most highly conserved block of basic amino acids within this region, 
reduced, but did not abrogate, nuclear FANCD2 localization in FA-D2 cells. These 
results establish that the functional NLS elements are harbored within the amino 
terminal 58 amino acids. While the classical bipartite NLS comprises two clusters of 
basic amino acids separated by a 10-12 amino acid linker region, exemplified by the 
NLS of nucleoplasmin [22,23], unconventional bipartite NLSs with extended linker 
lengths have also been described [24-26]. However, cNLS mapper searches for both 
conventional and unconventional bipartite NLSs and only detected the former [12]. In 
addition to monopartite and bipartite NLSs, at least two other classes of NLS have 
been described: tripartite containing three clusters of basic amino acids similar to 
those found in L-periaxin and the epidermal growth factor receptor (EGFR) family 
[27,28], as well as NLSs containing dispersed basic residues within a random coil 
structure such as that found for 5-lipoxygenase [29]. These NLSs are poorly 
characterized in comparison with their mono- and bi-partite counterparts and are not 
predicted by cNLS mapper or PSORT II amino acid prediction algorithms. While the 
crystal structure of the murine Fanci-Fancd2 heterodimer (ID2) has been solved, the 
majority of the NLS described in this study was not crystallized precluding 
speculation about the structure of this region [30]. It is also important to note that 
FANCD2 harbors several putative phosphorylation sites within the amino terminal 58 
 89 
 
amino acids (PhosphoSitePlus), which may also contribute to the regulation of its 
nuclear localization [31].  
Our studies suggest that FANCD2 is imported to the nucleus via an importin 
/-dependent mechanism as treatment with ivermectin, a broad-spectrum inhibitor of 
importin /-dependent nuclear import [13], results in markedly decreased exclusive 
nuclear localization of D2-NLS-GFP. Furthermore, using mass spectrometry we have 
recently detected importin 1, as well as the nuclear pore complex proteins NUP160 
and NUP155, in FANCD2 immune complexes (Supplemental Table 1). In summary, 
our functional analyses have revealed the following important points: 1) the NLS is 
necessary for the nuclear localization of FANCD2, 2) the FANCD2 NLS is required 
for the nuclear localization of a subset of FANCI, 3) the NLS is necessary for the 
efficient monoubiquitination of both FANCD2 and FANCI, and 4) the NLS is 
required for the localization of both FANCD2 and FANCI in chromatin. 
Consequently, FA-D2 cells expressing FANCD2 NLS deletion mutants are defective 
in the repair of ICLs. Our studies provide additional important insight into the domain 
structure of FANCD2, and suggest a novel FANCD2-dependent piggyback 
mechanism of FANCI nuclear import. Furthermore, our results suggest that FANCD2 
and FANCI are targeted to the nucleus as a heterodimer. These findings lend 
important insight into the structure and regulation of two poorly characterized tumor 
suppressor proteins with key early roles in the cellular ICL response. 
Here we have established that FANCI is, at least partially, dependent on 
FANCD2 for both its nuclear localization and chromatin association: In FA-D2 patient 
cells, as well as FA-D2 cells expressing the FANCD2 NLS mutants, FANCI localized 
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diffusely to the cytoplasm and nucleus. The introduction of wild type FANCD2 into 
these cells resulted in a large increase in exclusively nuclear FANCI as well as its 
chromatin localization, particularly following exposure to MMC. In contrast, we, and 
others, have observed robust nuclear localization of FANCD2 in FA-I cells, indicating 
that FANCD2 is not dependent on FANCI for its nuclear localization [32]. A previous 
study of the patient-derived FANCI R1299X nonsense mutant, which lacks its 
carboxy-terminal 30 amino acids, demonstrated that FANCI harbors a monopartite 
NLS in this region [32]. While loss of this NLS reduced FANCI nuclear accumulation, 
this NLS was not completely necessary for FANCI or FANCD2 nuclear accumulation, 
strongly suggesting the existence of alternative nuclear import mechanisms for both 
proteins, consistent with our data [32]. The elucidation of the crystal structure of the 
ID2 heterodimer indicates that the FANCD2 and FANCI NLSs are spatially separated 
within this structure [30], arguing against the simultaneous contribution of both NLSs 
to nuclear import of the ID2 complex. Taken together, these results suggest that 
FANCI localizes to the nucleus via FANCD2-independent and -dependent 
mechanisms (Fig. 6). These findings are also consistent with the observation that only 
a minor fraction of the cellular pools of FANCD2 and FANCI physically interact 
[8,9], reinforcing the concept of ID2 complex-independent functions for both proteins, 
such as that recently described by Chaudhury and colleagues [33]. A recent study has 
also established that a fraction of FANCD2 is transported to the nucleus following 
MMC exposure via an indirect interaction with importin 4 (IPO4), which is mediated 
by the C/EBP transcription factor [34]. While clearly important for ICL repair, this 
mechanism in unlikely to be the major mechanism of FANCD2 nuclear import as 
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robust levels of nuclear FANCD2 were observed in C/EBP-null mouse embryonic 
fibroblasts as well as cells depleted of IPO4 and C/EBP [34]. Nevertheless, this 
C/EBP/IPO4-dependent FANCD2 nuclear import mechanism could account for the 
low levels of nuclear FANCD2-N57 and FANCD2-N57 observed in our studies. 
Interestingly, we observed markedly increased MMC-inducible chromosome 
aberrations and DNA-PKCS pS2056 nuclear foci formation in FA-D2 cells expressing 
FANCD2-N57, compared to FA-D2 cells expressing LacZ. These results suggest 
that the FANCD2-N57 mutant may act in a dominant-negative manner. The FA-D2 
patient-derived cells used in this study are compound heterozygous for FANCD2 
mutations (see Materials and Methods). This variant is detectable by immunoblotting 
(see Fig. 4A, top panel) and is predicted to retain residual or partial function. Indeed, 
the vast majority of FA-D2 patient-derived cells retain residual FANCD2 function 
with complete loss of FANCD2 predicted to result in embryonic lethality [15]. Our 
results suggest that the FANCD2-N57 mutant interferes with residual FANCD2 
R1236H function, perhaps competing with FANCD2 R1236H for heterodimerization 
with FANCI, or in a manner analogous to missense p53 mutations, by assembling into 
nonfunctional homo-oligomers, the formation of which has been suggested by 
previous studies [30,35].    
Based on our findings, and those of several other groups, we propose the 
following model for early steps in the FA-BRCA pathway of ICL repair (Fig. 6). A 
subset of the total cellular pools of FANCD2 and FANCI associate in the cytoplasm to 
assemble into the ID2 heterodimer. The ID2 heterodimer is transported to the nucleus 
most likely via an importin /-mediated transport process, using the amino terminal  
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Figure 6. FANCD2-dependent and -independent mechanisms of FANCI nuclear 
localization. We propose that a subset of FANCI (blue) associates with FANCD2 
(red) in the cytoplasm, and that the ID2 heterodimer is transported to the nucleus via 
an importin α/β (brown)-mediated transport mechanism, using the amino terminal 
FANCD2 NLS (light green). Nuclear ID2 binds to DNA (orange) and is also 
phosphorylated by the ATM/ATR kinases (dark green). One or both of these events 
may trigger ID2 complex restructuring, facilitating FANCD2 and FANCI 
monoubiquitination by FANCL (black), UBE2T (yellow) and the FA core complex 
(not shown). 
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NLS of FANCD2. Once inside the nucleus the ID2 heterodimer is targeted to sites of 
ICL damage possibly via the association of FANCD2 with PCNA and the replication 
fork machinery [19]. Recent in vitro studies have demonstrated that FANCI binding to 
DNA is necessary for robust stimulation of the monoubiquitination of FANCD2 [36]. 
However, analysis of the ID2 crystal structure indicates that the FANCD2 K561 side 
chain, the site of monoubiquitination, is embedded within the ID2 interface [30]. 
Furthermore, a solvent accessible tunnel adjacent to FANCD2 K561 is predicted to be 
too small to accommodate the active site of the UBE2T ubiquitin-conjugating enzyme 
[30,37]. Therefore, either 1) monoubiquitination occurs on FANCD2 and FANCI 
monomers prior to ID2 heterodimerization or 2) binding of the ID2 complex to DNA 
leads to a conformational change in the ID2 structure leading to the exposure of 
K561R and FANCI K523, and their subsequent monoubiquitination, as has been 
proposed [36]. A recent study by Sareen and colleagues suggests that activation of the 
FA-BRCA pathway coincides with dissociation of FANCD2 and FANCI [38]. ID2 
dissociation is triggered by ATR/ATM-mediated phosphorylation of a cluster of at 
least six FANCI SQ motifs, and is followed by the monoubiquitination of FANCD2 
[38,39]. Once monoubiquitinated, FANCD2 can then facilitate the recruitment of 
several structure specific nucleases, including FAN1 and FANCP/SLX4, initiating the 
process of ICL removal [40-46]. 
 
 95 
 
Materials and Methods 
Cell culture  
COS-7, HeLa, and IMR90 cells were grown in Dulbecco's modified Eagle's medium 
(DMEM) supplemented with 12% v/v FBS, L-glutamine and penicillin/streptomycin. 
293FT viral producer cells (Invitrogen) were cultured in DMEM containing 12% v/v 
FBS, 0.1 mM non-essential amino acids (NEAA), 1% v/v L-glutamine, 1 mM sodium 
pyruvate and 1% v/v penicillin/streptomycin. PD20 FA-D2 (FANCD2
hy/-
) cells were 
purchased from Coriell Cell Repositories (Catalog ID GM16633). These cells harbor a 
maternally inherited A-G change at nucleotide 376 that leads to the production of a 
severely truncated protein, and a paternally inherited missense hypomorphic (
hy
) 
mutation leading to a R1236H change [14]. To generate stable lines expressing wild 
type or mutant FANCD2, FA-D2 cells were infected with pLenti6.2-FANCD2 
(Invitrogen) lentivirus, followed by selection in DMEM supplemented with 12% v/v 
FBS, L-glutamine, penicillin/streptomycin and 2 μg/ml blasticidin. KEAE FA-D2 
cells and KEAE FA-D2 + FANCD2 cells were a kind gift from Detlev Schindler of 
the University of Würzburg [15]. These cells were telomerase immortalized using 
pBABE-hTERT and grown in DMEM supplemented with 12% v/v FBS, L-glutamine, 
penicillin/streptomycin and 0.75 μg/ml puromycin.   
  
Antibodies and immunoblotting  
For immunoblotting analysis, cell pellets were washed in PBS and lysed in 2% w/v 
SDS, 50 mM Tris-HCl, 10 mM EDTA. Proteins were resolved on NuPage 3-8% w/v 
Tris-Acetate or 4-12% w/v Bis-Tris gels (Invitrogen) and transferred to polyvinylidene 
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difluoride (PVDF) membranes. The following antibodies were used: rabbit polyclonal 
antisera against FANCD2 (NB100-182; Novus Biologicals), FANCI (Dr. Patrick 
Sung, Yale University), H2A (07-146; Millipore), and mouse monoclonal sera against 
α-tubulin (MS-581-PO; Neomarkers), GFP (sc-9996; Santa Cruz), and V5 (R96025; 
Invitrogen). 
  
Immunofluorescence microscopy  
For immunofluorescence microscopy (IF) analysis, cells were seeded in 4-well tissue 
culture slides (BD Falcon) and treated with mitomycin C (MMC) for 18 h.  Soluble 
cellular proteins were pre-permeabilized with 0.3% v/v Triton X-100 and cells were 
fixed in 4% w/v paraformaldehyde and 2% w/v sucrose at 4°C followed by 
permeabilization in 0.3% v/v Triton X-100 in PBS. Fixed cells were blocked for 30 
minutes in antibody dilution buffer (5% v/v goat serum, 0.1% v/v NP-40, in PBS) and 
incubated with primary antibody for 1 h. Cells were washed three times in PBS, as 
well as permeabilization buffer, and incubated for 30 min at room temperature with an 
Alexa Fluor 488-conjugated secondary antibody combined with Texas Red labeled 
phalloidin. The slides were counterstained and mounted in vectashield plus 4‟6-
diamidine-2-phenylindole dihydrochloride (DAPI) (Vector Laboratories). Nuclear foci 
were analyzed using a Zeiss AxioImager.A1 upright epifluorescent microscope with 
AxioVision LE 4.6 image acquisition software.  Primary antibodies used for IF were 
anti-FANCD2 (NB100-182; Novus Biologicals), anti-FANCI (Dr. Patrick Sung, Yale 
University), anti-DNA-PKCS pS2056 (ab18192; Abcam), and anti-V5 (R960-25; 
Invitrogen). 
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Plasmids, site-directed mutagenesis, and transient transfections  
The full length, N57, and N100 FANCD2 cDNA sequences were TOPO cloned into 
the pENTR⁄D-TOPO (Invitrogen) entry vector, and subsequently recombined into the 
pLenti6.2/V5-DEST (Invitrogen) destination vector and used to generate lentivirus for 
the generation of stable cell lines. The FANCD2-KRR4NNN (FANCD2-3N) cDNA 
was generated by site-directed mutagenesis of the wild type FANCD2 cDNA using the 
Quikchange Site-directed Mutagenesis Kit (Stratagene). The forward and reverse 
oligonucleotide sequences used are as follows: FP, 5‟-
TTCACCATGGTTTCCAACAACAACCTGTCAAAATCTGAGG-3‟; RP, 5‟-
CCTCAGATTTTGACAGGTTGTTGTTGGAAACCATGGTGAA -3‟. The FANCD2 
GFP fusion vectors D2-1-27-GFP, D2-24-55-GFP, and D2-1-58-GFP were generated 
by PCR amplifying the coding sequences of amino acids 1-27, 24-55, or 1-58 of 
FANCD2 and directionally cloning these fragments into the multiple cloning site of 
pEGFP-N1 (Clontech). The FANCI-GFP construct was a gift from Tony Huang in the 
Department of Biochemistry at New York University School of Medicine. COS-7, 
HeLa, and IMR90 cells were transiently transfected with plasmid DNA using Fugene 
6 (Roche) at a 1:3 ratio (g DNA:L Fugene 6) in Opti-MEM. After incubating for 24 
h, GFP fluorescence was monitored using a Zeiss AxioImager X-Cite series 120Q 
inverted fluorescence microscope with AxioVision LE 4.8 image acquisition software. 
Ivermectin (Sigma) was added to a final concentration of 25 M 4 h following 
transfection.   
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Cellular fractionation  
Soluble proteins were removed by extraction in cytoskeletal buffer (CSK) (10 mM 
PIPES pH 6.8, 300 mM sucrose, 100 mM NaCl, 3 mM MgCl2, 1 mM EGTA, and 
0.5% v/v Triton-X-100) for 10 minutes at 4
o
C. Pellets were washed once with CSK 
buffer, lysed in SDS sample buffer (2% w/v SDS, 50 mM Tris-HCl pH 7.4, 10 mM 
EDTA), boiled for 15 min, followed by sonication for 10 s at 10% amplitude using a 
Fisher Scientific Model 500 Ultrasonic Dismembrator.  
  
Chromosome breakage analysis  
Cells were incubated in the absence or presence of MMC for 18 h. Prior to harvesting, 
cells were treated with 0.1 ug/ml Colcemid (Gibco/Invitrogen) for 2 h; pellets were 
then incubated in 0.075 M KCl at 37°C for 18 min, followed by fixation in Carnoy‟s 
fixative (3:1 methanol:glacial acetic acid). Cells were dropped onto chilled slides, air-
dried, and then stained with 2.5% w/v Giemsa solution (Sigma). Metaphases were 
analyzed using a Zeiss AxioImager.A1 upright epifluorescent microscope with Axio 
Vision LE 4.6 image acquisition software. 
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Abstract 
Fanconi anemia (FA) is a rare genetic disease characterized by bone marrow failure, 
congenital defects, and increased cancer susceptibility. FA is caused by mutation in 
any of 19 known genes. The protein products of these genes function collectively in 
the FA-BRCA pathway to repair DNA interstrand-crosslinks (ICLs). Upon exposure 
to ICL-inducing agents, the FA core complex catalyzes the monoubiquitination of the 
FANCD2 and FANCI proteins, activating these proteins for ICL repair. FANCD2 is 
also posttranslationally modified by phosphorylation following exposure to DNA 
damaging agents and upon disruption of DNA replication. The DNA damage-
inducible posttranslational regulation of the FA pathway has been extensively studied, 
however, few studies have explored the regulation of the FANCD2 and FANCI 
proteins independent of DNA damage. In this study, we have determined that 
FANCD2 is phosphorylated in a DNA damage-independent manner, which appears to 
be mediated by CDK and is maximal during S phase, coinciding with FANCD2 
monoubiquitination. We have also identified a putative CDK phosphorylation site 
cluster proximal to K561. Phosphorylation at this cluster has a negative regulation of 
FANCD2 monoubiquitination. We hypothesize that CDK-mediated FANCD2 
phosphorylation is critical for the efficient regulation of FANCD2 function during S 
phase. 
 
Introduction 
Fanconi anemia (FA) is a rare recessive disease, characterized by congenital 
abnormalities, progressive pediatric bone marrow failure, and heightened cancer 
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susceptibility [1].  FA is caused by mutation in any one of 19 genes (FANCA, -B, -C, -
D1/BRCA2, -D2, -E, -F, -G, -I, -J/BRIP1, -L, -M, -N/PALB2, -P/SLX4, O/RAD51C, 
Q/ERCC4, R/RAD51, S/BRCA1, T/UBE2T) [2-4]. The FA proteins function 
cooperatively in the FA-BRCA pathway to repair DNA interstrand crosslinks (ICLs) 
and to prevent chromosome instability. The core complex, comprised of 
FANCA/B/C/E/F/G/L, along with the E2 conjugating enzyme FANCT, FANCM, 
FAAP100/24/20, and MHF1/2 catalyze the monoubiquitination of the FANCD2 and 
FANCI proteins [4,5]. This central activation step promotes FANCD2 and FANCI co-
localization to discrete nuclear foci with several downstream DNA repair proteins, 
including FANCS/BRCA1 and NBS1 [6-9]. Monoubiquitinated FANCD2 has been 
shown to recruit the structure specific endonucleases FAN1 and FANCP/SLX4, which 
suggests that this modified form of FANCD2 functions to promote one or more 
incision steps during the ICL repair process [10,11]. FANCD2 and FANCI are also 
posttranslationally modified by phosphorylation in response to DNA damage by ATM 
(Ataxia-telangiectasia mutated) and ATR (ATM and Rad3-related). ATM 
phosphorylates FANCD2 in response to IR exposure independently of 
monoubiquitination [12]. Phosphorylation of FANCD2 by ATR promotes FANCD2 
monoubiquitination in response to exposure to ICL-inducing agents and is important 
in its function in ICL repair [13]. FANCI phosphorylation by ATM/ATR on six 
SQ/TQ residues has been linked to activation of the FA-BRCA pathway, potentially 
by promoting the dissociation of the FANCD2-FANCI heterodimer [14,15].  
 Although the main focus concerning FANCD2 has been based on DNA 
damage activation, FANCD2 has also been shown to be monoubiquitinated during 
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unperturbed cell cycle progression in S phase, where it co-localizes with BRCA1 and 
RAD51 [16]. With the addition of hydroxyurea (HU), which arrests DNA replication, 
FANCD2 has been shown to protect stalled replication forks from degradation by 
MRE11, and to promote replication restart at stalled replication forks by recruiting and 
interacting with CtIP (CtBP-interacting protein) [17,18]. These studies suggest that 
FANCD2 has many roles outside of the more recognized DNA damage inducible 
function, specifically during the cell cycle.  
 In this study, we have determined that FANCD2 is phosphorylated in a DNA 
damage-independent manner, which we believe is essential for the regulation of 
FANCD2 function during unperturbed S phase. Many DNA repair proteins are 
regulated by cyclin-dependent kinase (CDK) mediated phosphorylation, such as 
BRCA1 and NBS [19,20]. Here we show that FANCD2 is a substrate of CDK through 
immunoprecipitation studies as well as CDK inhibitor experiments. Importantly, we 
have discovered and are beginning to characterize a putative CDK site cluster in 
FANCD2 that is positioned proximal to FANCD2s site of monoubiquitination. 
Missense mutations of these sites yields unexpected results, a phospho-mimetic 
mutant fails to induce a response to DNA replication or damaging agents and a 
phospho-dead mutant is constitutively activated. The findings from this study establish 
novel phosphorylation of FANCD2 in unperturbed S phase and reveal a CDK 
phosphorylation site cluster that is posttranslationally modified to negatively regulate 
FANCD2 monoubiquitination. 
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Results 
FANCD2 is phosphorylated in the absence of DNA damage 
Initial findings from a previous study using FANCD2 patient cells expressing 
FANCD2-WT, FANCD2-K561R, and truncation mutants, suggested that FANCD2 
may be phosphorylated in the absence of DNA damage (data not shown). In order to 
analyze the phosphorylation of FANCD2 under these conditions, a lambda 
phosphatase assay was performed. Lambda phosphatase cleaves phosphorylated 
serine, threonine, and tyrosine residues [21]. HeLa, U2OS, COS7, and BJ-TERT cells 
were treated with and without MMC and lysates were incubated in the presence and 
absence of lambda phosphatase (Fig. 1A). When comparing incubation with and 
without lambda phosphatase, the electrophoretic mobility of FANCD2 increases in 
both the presence and absence of MMC, indicating that FANCD2 is phosphorylated 
independent of DNA damage. It is interesting to note that this is not seen with FANCI.  
 To ensure this finding is due to phosphorylation, a lambda phosphatase assay 
was done using HeLa, FA-D2 patient-derived cells stably express the empty vector, 
FANCD2-WT, and FANCD2-K561R, which were treated for the indicated times with 
lambda phosphatase (Fig. 1B). Reaction products were then run on a Phos-tag gel; 
Phos-tag is a novel phosphate-binding tag that binds phosphorylated proteins [22]. 
Treatment with lambda phosphatase causes the stabilization of non-phosphorylated 
FANCD2 and limits the isoforms present when compared to lack of  treatment. To 
ensure the molecular weight difference in FANCD2 was due to the cleavage of 
phosphate groups and not an unforeseen interaction with the lambda phosphatase 
enzyme, protein phosphatase 1 (PP1) enzyme was used (Fig. 1C). This enzyme
 112 
 
Figure 1. FANCD2 is phosphorylated in the absence of DNA damage. (A) HeLa, 
U2OS, COS-7, and BJ-TERT cells were incubated in the absence (-) and presence (+) 
of 250 nM MMC for 18 h and whole-cell lysates were subsequently treated with (+) 
and without (-) lambda phosphatase for 2 h 30°C and immunoblotted with antibodies 
against FANCD2, FANCI, and α-tubulin. (B) HeLa, FA-D2 cells with empty plasmid 
or stably expressing FANCD2-WT, and FANCD2-K561R were incubated with 
lambda phosphatase for 2, 4, 16 h at 30°C and run on a SuperSep Phos-tag gel. They 
were immunoblotted against FANCD2 and V5. (C) HeLa and U2OS cells were 
incubated with lambda phosphatase or PP1 for 2 h at 30°C and immunoblotted against 
FANCD2. ∆, molecular weight shift difference between nonphosphorylated and 
phosphorylated FANCD2.
 113 
 
.
 114 
 
cleaves phosphates from serine and threonine residues. Much like lambda 
phosphatase, PP1 also caused FANCD2 to migrate faster in the gel in both HeLa and 
U2OS cells, indicating a true phosphorylation pattern. Taken together, this data 
indicates that FANCD2 is phosphorylated on several residues, in a DNA damage-
independent manner. 
 
FANCD2 phosphorylation is maximal in S phase 
It is known that FANCD2 is activated through monoubiquitination during S phase of 
the cell cycle; however, the regulation behind this cycle dependent posttranslational 
modification is currently unknown [16]. To determine if FANCD2 is differentially 
phosphorylated throughout the cell cycle, several cell synchronizations were 
performed. Using HeLa cells, a nocodazole block was performed, blocking the cells in 
early M phase (Fig. 2A). Cells were then released for the indicated times and cell 
pellets were separated into three, treating with and without lambda phosphatase for 2 
h, and the third was fixed and stained with propidium iodide for FACS analysis. 
Although there is a molecular weight shift difference when looking at FANCD2 via 
western blot, this shift in migration is most prominent at 12 and 15 h post-release, 
correlating with S phase of the cell cycle. Again, when probing for FANCI, no 
molecular weight shift was observed. Cyclin A was used as a cell cycle marker, as it is 
active and upregulated in S and G2 phases of the cell cycle [23]. To explore FANCD2 
phosphorylation during the cell cycle, a second synchronization method was 
performed. Using both HeLa (Fig. 2B) and U2OS cells (Fig. S1), a double thymidine 
block arrest was used to synchronize in G1/S phase of the cell cycle. A lambda
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Figure 2. FANCD2 phosphorylation is maximal in S phase. (A) HeLa cells were 
synchronized by nocodazole block or double thymidine block (B). The cell cycle 
phase was determined by flow cytometric analysis of DNA content and whole-cell 
lysates were incubated in the absence (-) and presence (+) of lambda phosphatase for 2 
h at 30°C and immunoblotted with antibodies against FANCD2, FANCI, and Cyclin 
A. AS, asynchronous whole-cell lysate. 
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phosphatase assay and FACs analysis was then performed, and in a similar manner as 
the nocodazole block, a maximal molecular weight shift difference is seen 0-4 h post-
release. This is indicative of S phase of the cell cycle, suggesting there is a DNA 
damage independent phosphorylation of FANCD2 that correlates with its 
monoubiquitination.  
 
Non-DNA damage inducible phosphorylation of FANCD2 is independent of 
ATM, ATR, and the core complex member FANCA 
It is known that FANCD2 and FANCI are phosphorylated by the DNA damage 
response kinases ATM and ATR [12-14]. To test if ATM was the kinase responsible 
for the phosphorylation of FANCD2 in S phase seen via the lambda phosphatase 
assay, PEBS (ATM-/-) and YZ5 (ATM+/+) fibroblasts were used for a double 
thymidine block and subsequent lambda phosphatase assay, as described previously 
(Fig. 3A). If ATM is essential for this posttranslational modification, the molecular 
weight difference in FANCD2 treated with and without lambda phosphatase would be 
absent or reduced. In comparing PEBS and YZ5 cells, there is no difference in 
FANCD2s electrophoretic mobility with the addition of the lambda phosphatase 
enzyme, indicating this phosphorylation is largely independent of ATM. To determine 
ATRs importance in FANCD2s phosphorylation in the absence of DNA damage and 
in S phase of the cell cycle, 066 Seckel patient lymphoblasts (ATR-/-) and wild-type 
lymphoblasts were then used  (Fig. 3B). Similar to the results seen in ATM deficient 
cells, ATR does not appear to be crucial for this mobility in FANCD2. The FA core 
complex is responsible for orchestrating FANCD2s monoubiquitination;
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Figure 3. Non-DNA damage inducible phosphorylation of FANCD2 is 
independent of ATM, ATR, and the core complex member FANCA. (A) PEBS 
(ATM-/-) and YZ5 (ATM+/+) fibroblasts were synchronized by double thymidine and 
released for 0 and 2 h followed by treatment with lambda phosphatase for 2 h at 30°C 
and immunoblotted with antibodies to FANCD2, FANCI, ATM, and α-tubulin. (B) 
066 (ATR-/-) and PD7L (WT) lymphoblasts were synchronized by double thymidine 
block and released for 0 and 2 h followed by treatment with lambda phosphatase for 2 
h at 30°C and immunoblotted with antibodies against FANCD2, FANCI, ATR, 
CHK1, and pS345 CHK1. (C) 6914 (FA-A) and 6914 + FANCA were synchronized 
by double thymidine block and released for 0 and 2 h followed by treatment with 
lambda phosphatase for 2 h at 30°C and immunoblotted with antibodies against 
FANCD2, FANCI, FANCA, and α-tubulin.
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therefore, we next assessed the ability of FANCD2 to become phosphorylated in the 
absence of FANCA. FA-A (6914) and FA-A corrected cells (6914 + FANCA) were 
arrested in early S phase by double thymidine treatment, followed by incubation in the 
presence and absence of lambda phosphatase (Fig. 3C). As seen in the ATR and ATM 
deficient cells, in the absence of FANCA, there is still a phosphorylation shift 
visualized. These results combined suggest that the DNA damage response kinases are 
not responsible for FANCD2s phosphorylation in the cell cycle and this 
phosphorylation event occurs either upstream or independently of FANCD2s 
monoubiquitination. To corroborate FANCD2 phosphorylation acting upstream or 
independently of FANCD2s monoubiquitination, FA-D2 + empty, FANCD2, and 
K561R cell lines were used incubated with lambda phosphatase for 2, 4, and 16 h 
(Fig. S2). FANCD2 K561R is unable to become monoubiquitinated; however, a 
molecular weight shift difference is still seen. This indicates that monoubiquitination 
is not essential for FANCD2s phosphorylation.   
 
FANCD2 is a potential substrate of CDK phosphorylation 
Cell cycle progression is regulated through phosphorylation by CDKs [24]. We next 
assessed whether FANCD2 was a substrate of CDK phosphorylation by using  
FA-D2 patient cells stably expressing LacZ-V5 or FANCD2-V5 and performing an 
immunoprecipitation (IP) (Fig. 4A). V5 agarose was used to pull down FANCD2-V5. 
A pan phospho serine antibody was then used, which recognizes phosphorylated 
substrates of CDK, and FANCD2 is seen in the FA-D2 patient cell line expressing 
FANCD2. A second IP was performed using a different cell system, U2OS cells stably
 121 
 
Figure 4. FANCD2 is a potential substrate of CDK phosphorylation. (A) FA-D2 
cells stably expressing LacZ-V5 and FANCD2-V5 were immunoprecipitated with 
anti-V5 agarose and immune complexes were immunoblotted with anti-FANCD2 and 
anti-pSCDK. (B) U2OS and U2OS cells stably expressing 3X FLAG FANCD2-WT 
were immunoprecipitated with anti-FLAG agarose and immune complexes were 
immunoblotted with anti-FANCD2, anti-FLAG, and anti-pSCDK. (C) U2OS 3X 
FLAG FANCD2 immunoprecipiated as shown in (B), was used for phospho 
enrichment and further mass spectrometry analysis revealed several phosphorylated 
FANCD2 isoforms.
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expressing 3XFLAG tagged FANCD2 (Fig. 4B). Here we used FLAG agarose and 
performed an IP with U2OS and U2OS 3X FLAG-FANCD2 fibroblasts. Similar 
results were obtained as with FA-D2 FANCD2-V5; FANCD2 is a substrate of CDK as 
seen through the pan phospho serine antibody. The U2OS 3XFLAG FANCD2 IP was 
then run on a commassie gel in triplicate and the FANCD2 bands were combined and 
a tryptic digestion was performed in preparation for mass spectrometry (Fig. S3). 
Using TiO2 phosphopeptide enrichment, these samples were analyzed for phospho 
peptides (Fig. 4C). Several known ATM/ATR sites were found in this sample, as well 
as one serine protein site, S692, which resides in the phosphoCDK cluster proximal to 
K561. The CDK consensus sequence is [S/T*]PX[K/R], however, known DNA repair 
proteins, such as BRCA1, have been shown to be phosphorylated by CDK through 
only containing S/P of the consensus sequence. 
 
Treatment with CDK inhibitor purvalanol A alters FANCD2s phosphorylation 
shift 
As it was determined that FANCD2 is a potential substrate of CDK, we wanted to 
establish which CDK was responsible. If maximal FANCD2 phosphorylation occurs 
during S phase of the cell cycle, CDK2 could be the potential kinase responsible. In 
order to determine a specific CDK was responsible for FANCD2s non-DNA damaging 
phosphorylation, various CDK inhibitors with differing specificities were utilized 
(Fig. 5A). HeLa cells were incubated with each indicated inhibitor for 24 h and a 
lambda phosphatase assay was performed to determine if a specific CDK is required 
for FANCD2s phosphorylation (Fig. 5B). Two chemicals that comprise CDK2
 124 
 
 
Figure 5. Treatment with CDK inhibitor purvalanol A alters FANCD2s 
phosphorylation shift. (A) Table depicting CDK inhibitors and their specific targets. 
(B) HeLa cells were treated for 24 h with 10 μM Olomoucine, 10 μM Olomoucine II, 
10 μM Purvalanol A, 10 μM RO-3306, and 20 μM Roscovatine and whole-cell lysates 
were treated in the absence (-) and prescence (+) of lambda phosphatase for 2 h at 
30°C and immunoblotted with antibodies against FANCD2. (B) HeLa cells were 
treated with 10 uM Purvalanol A and 10 uM RO-3306 for 2, 4, 8, 24 h and incubated 
with (+) and without (-) lambda phosphatase. Immunoblotting was performed and 
antibodies against FANCD2 and α-tubulin were used.
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inhibition, Purvalanol A and Roscovitine, were shown to reduce FANCD2s mobility 
with the addition of the lambda phosphatase enzyme, indicating CDK2 could be 
needed. To further examine treatment with CDK inhibitors, HeLa cells were incubated 
for 2, 4, 8, or 24 h with either the CDK2 inhibitor Purvalanol A or the CDK1 specific 
inhibitor RO-3306 (Fig. 5C). A lambda phosphatase assay was then performed. As 
expected from the previous result, RO-3306 does not have an effect on FANCD2s 
phosphorylation. However, treatment with Purvalanol A, specifically for 4 and 8 h, 
depletes the mobility shift of FANCD2 with the addition of the enzyme. These results 
indicate CDK2 could be the potential kinase resulting in FANCD2s phosphorylation 
during S phase of the cell cycle.  
 
FANCD2 contains a conserved putative CDK consensus site cluster 
As the previous results suggest that FANCD2 is a substrate of CDK, the FANCD2 
sequence was analyzed for potential CDK phosphorylation sites. A multiple sequence 
alignment of FANCD2 found strong evolutionary conservation in a cluster of three 
S/P sites: S525, S624, S726 (Fig. 6A). Interestingly, when looking at the murine 
crystallized structure of FANCD2, this putative CDK cluster is situated in close 
proximity to FANCD2s monoubiquitination site (Fig. 6B). As previous results have 
established a connection between maximal FANCD2 phosphorylation occurring 
during S phase, which is when FANCD2 is monoubiquitinated during the cell cycle, 
the position could shed light on FANCD2s activation. It is important to note that the 
S/P site found through mass spec analysis, S692, is also situated within this cluster, 
albeit on a short uncrystallized loop. To determine the functional significance of the 
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Figure 6. FANCD2 contains a conserved putative CDK consensus site cluster. 
(A). A Clustal Omega multiple sequence alignment of three putative CDK 
phosphorylation sites, S525, S624, S726, in FANCD2 demonstrates strong 
evolutionary conservation. (B) Region of the mouse Fancd2 crystal structure 
represented as both surface and ribbons with S/P CDK consensus (teal) and the 
monoubiquitination site (yellow) indicated, using the program Discovery Studio. (C) 
FA-D2 cells stably expressing empty, FANCD2-WT, FANCD2-TA, and FANCD2-
TD were incubated in the absence (-) and presence (+) of 250 nM MMC for 18 h, and 
whole-cell lysates were immunoblotted with antibodies to FANCD2, V5, FANCI and 
α-tubulin. The FANCD2-V5 and FANCI L/S ratios are the ratios of 
monoubiquitinated to nonubiquitinated protein, and were calculated by measuring 
protein band intensities using ImageJ image processing and analysis software 
(http://rsb.info.nih.gov/ij/). 
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putative CDK cluster, we generated two missense mutants in S525, S624, S726. These 
sites were mutated into either phospho-dead triple alanine (TA) or phospho-mimetic 
triple aspartic acid (TD) mutants. The FANCD2 cDNAs were cloned into the 
pLenti6.2 lentiviral vector that contains a carboxy-terminal V5 tag. FA-D2 patient-
derived cells were used to stably express the empty vector, wild type FANCD2 and the 
missense mutants. To determine the consequences of mutating the putative CDK site 
cluster, the FA-D2 cell lines were then treated with and without MMC to determine 
their monoubiquitination efficiency (Fig. 6C). Although these mutations did not 
abrogate FANCD2 monoubiquitination, the TA mutant is constitutively activated and 
the TD mutant is unable to elicit a monoubiquitination response with the addition of 
damage. FANCI monoubiquitination is unaffected by the mutation of the FANCD2 
phosphorylation sites. To further study the functional effect of mutating these 
conserved phosphorylation residues, FA-D2 + empty, FANCD2-WT, TA, and TD 
cells were incubated with and without either HU or aphidicolin (APH) (Fig. S5). As 
we believe these residues are important in non-DNA damage inducible activation of 
FANCD2, it is important to explore DNA replication inhibitors, as FANCD2 is active 
during S phase of the cell cycle. HU transiently stalls replication by causing an 
imbalance in the deoxyribonucleoside triphosphate pool and APH inhibits DNA 
polymerase α [25,26]. Similar to the results obtained when treating with MMC, the TA 
mutant appears to be constitutively monoubiquitinated, while the TD mutant fails to 
become monoubiquitinated following exposure to the replicative inhibitors. 
Interestingly, when looking at CHK1 pS345 and RPA pS3/4, both mutants have an 
increase without the addition of treatment. These are markers for blocked DNA 
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replication, suggesting that mutating these phosphorylation sites causes inefficient 
DNA replication. Taken together, these results demonstrate the importance of these 
sites in FANCD2 function and further analysis must be performed to determine their 
mechanism of action and specific purpose in DNA replication.  
 
Discussion 
Although FANCD2 has been shown to function in unperturbed S phase of the cell 
cycle, how this is regulated has not been studied [16]. In this study, with the use of 
lambda phosphatase assays, we have revealed novel DNA damage-independent 
phosphorylation of FANCD2. Several cell lines show FANCD2 having an increase in 
electrophoretic mobility through an SDS Page gel with the addition of lambda 
phosphatase, indicating the cleavage of phosphate groups from the protein during 
incubation. This variance is not seen in FANCI, even after the addition of MMC. 
Although we know FANCI is phosphorylated by ATM/ATR with the addition of 
damage, this inability to visualize a molecular weight shift difference, due to 
phosphate cleavage, could be explained by how extensive the phosphorylation is  [15].  
Currently, six S/TQ sites have been described to be phosphorylated by ATM/ATR 
[14]. The limited number of residues phosphorylated could be the reason for no visible 
shift difference seen in this assay. FANCD2 and FANCI are very large proteins, 1451 
and 1328 amino acids, respectively [27]. In order to see this slight shift in protein 
molecular weight, due to their size, the immunoblot must be extensively run and the 
ability of FANCD2 phosphorylation to be visualized could mean it is extensively 
phosphorylated. It is important to note that the shift is also seen with incubation with 
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the second phosphatase, PP1. Interestingly, we have found that maximal FANCD2 
phosphorylation, as seen through the lambda phosphatase assay, occurs at S phase. 
This has been visualized by double thymidine block, as well as a nocodazole block. 
This suggests that FANCD2s function in the cell cycle could be regulated through 
phosphorylation.   
 DNA damage inducible FANCD2 phosphorylation has been widely studied, so 
it is necessary to determine if the key regulatory proteins involved in this well-known 
posttranslational modification are essential for the non-DNA damaging regulation of 
FANCD2 [12,16,28]. With the use of patient fibroblast and lymphoblasts, we found 
that the extensive phosphorylation of FANCD2, in S phase, is unaffected by the 
absence of ATM, ATR, and FANCA. Due to FANCD2s monoubiquitination in S 
phase and, now seen, phosphorylation, we next wanted to determine if these 
posttranslational modifications were reliant on one another [16]. In using FA-D2 
patient cells expressing FANCD2-K561R, the monoubiquitination deficient mutant, 
this shift in FANCD2 in the presence of lambda phosphatase is still observed. This 
would indicate that this phosphorylation event occurs upstream of monoubiquitination 
or is monoubiquitination-independent. Importantly, with the addition of the 
phosphatase throughout this study, monoubiquitinated FANCD2 is still present. This 
suggests that this phosphorylation does not affect the stabilization of 
monoubiquitinated FANCD2 and monoubiquitination is not essential for 
phosphorylation.  
 If FANCD2 is indeed phosphorylated during the cell cycle, the potential kinase 
responsible is a CDK. As mentioned, several DNA repair proteins are phosphorylated 
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by CDKs, so we decided to determine if FANCD2 was a substrate of CDK 
phosphorylation [19,20]. In using two different cell systems and an antibody, that 
specifically recognizes substrates of CDKs through its known consensus sequence; we 
found that FANCD2 is potentially a substrate of CDK. To try to determine which 
residues are phosphorylated and narrow down our sites of interest, we used the U2OS 
3XFLAG FANCD2 immunoprecipitation to enrich for phospho peptides and analyze 
by mass spectrometry. Several ATM/ATR sites were enriched, however, a putative 
CDK consensus site that has not been studied due to its lack of sequence conservation 
was also found, S592. We then optimized several CDK inhibitors to try to focus on a 
specific CDK responsible. Correlating with our finding that FANCD2s 
phosphorylation is maximal during S phase, the inhibitor Purvalanol A seemed to limit 
FANCD2s molecular weight shift with the addition of lambda phosphatase. This 
inhibitor is specific towards CDK2, with some inhibition of CDK1 [29]. We further 
compared the CDK1 specific inhibitor, RO-3306, and Purvalanol A and found that 
incubation with the CDK2 inhibitor for 4 and 8 h limited FANCD2s phosphorylation. 
This suggests that FANCD2s phosphorylation during S phase is regulated by CDK2.  
Through initial sequence and structural analysis, several important putative 
CDK phosphorylation sites have been discovered. The CDK S/P residues S525, S624, 
and S726 were highly conserved amongst various species and are situated proximal to 
FANCD2s monoubiquitination site and form a cluster with the mass spectrometry 
phospho peptide found, S592. This site, however, is located on a short uncrystallized 
loop in FANCD2. Through site-directed mutagenesis, S525, S624, S726 were mutated 
to alanines (TA), phospho-dead, or aspartic acid (TD), phospho-mimetic, residues. 
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Originally, due to FANCD2s extensive phosphorylation occurring when it is 
monoubiquitinated in S phase, we hypothesized that these sites may activate 
FANCD2. Surprisingly, when FA-D2 patient cells expressing the phosphorylation 
mutants were treated with MMC, the phospho-dead mutant is constitutively 
monoubiquitinated and the phospho-mimetic mutant is unable to induce 
monoubiquitination after damage. This would indicate, not only the importance of 
these residues in FANCD2s function, but also that phosphorylation at these sites may 
inhibit FANCD2 monoubiquitination. Although maximal FANCD2 phosphorylation is 
seen during S phase, these sites may not play a role in that function, but instead have a 
novel regulatory effect on FANCD2 for its inactivation. As we are interested in DNA 
damage-independent regulation of FANCD2 and we know it functions at stalled 
replication forks in unperturbed S phase, the FA-D2 cells were treated with two DNA 
replication inhibitors. With the addition of APH or HU, FANCD2-TA is constitutively 
monoubiquitinated and FANCD2-TD is unable to show a response. Both mutations, 
however, have an increase in CHK1 pS345 and RPA pS4/8, indicating replication is 
blocked in both cases. Based on these findings, we predict that although these sites 
may not be linked to FANCD2s cell cycle phosphorylation, they have an important 
effect on FANCD2 function in response to DNA damaging and replicative stress 
inducing agents. Further analysis on these mutants must be done in order to (A) 
determine if CDK2 is the kinase responsible for this phosphorylation, (B) establish the 
function of this posttranslational modification on the FA-BRCA pathway, and (C) 
extensively characterize how mutation of these residues affect FANCD2 function. 
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Materials and Methods 
Cell culture  
COS-7, HeLa, U2OS, U2OS 3X FLAG FANCD2, BJTERT, PEBS, YZ5, 6914, and 
6914 + FANCA cells were grown in Dulbecco's modified Eagle's medium (DMEM) 
supplemented with 12% v/v FBS, L-glutamine and penicillin/streptomycin. 066 and 
PD7L cells were grown in Roswell Park Memorial Institute medium (RPMI) 
supplemented with 18% v/v FBS, L-glutamine and penicillin/streptomycin. 293FT 
viral producer cells (Invitrogen) were cultured in DMEM containing 12% v/v FBS, 0.1 
mM non-essential amino acids (NEAA), 1% v/v L-glutamine, 1 mM sodium pyruvate 
and 1% v/v penicillin/streptomycin. PD20 FA-D2 (FANCD2
hy/-
) cells were purchased 
from Coriell Cell Repositories (Catalog ID GM16633). These cells harbor a 
maternally inherited A-G change at nucleotide 376 that leads to the production of a 
severely truncated protein, and a paternally inherited missense hypomorphic (
hy
) 
mutation leading to a R1236H change [30]. To generate stable lines expressing wild 
type or mutant FANCD2, FA-D2 cells were infected with pLenti6.2-FANCD2 
(Invitrogen) lentivirus, followed by selection in DMEM supplemented with 15% v/v 
FBS, L-glutamine, penicillin/streptomycin and 2 μg/ml blasticidin. Cells were treated 
with the CDK inhibitors Olomoucine (Acros), Olomoucine II (Santa Cruz), Purvalanol 
A (Santa Cruz), RO-3306 (Santa Cruz), and Roscovitine (Acros) as indicated. 
  
Antibodies and immunoblotting  
For immunoblotting analysis, cell pellets were washed in PBS and lysed in 2% w/v 
SDS, 50 mM Tris-HCl, 10 mM EDTA followed by sonication for 10 s at 10% 
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amplitude using a Fisher Scientific Model 500 Ultrasonic Dismembrator. Proteins 
were resolved on NuPage 3-8% w/v Tris-Acetate or 4-12% w/v Bis-Tris gels 
(Invitrogen) and transferred to polyvinylidene difluoride (PVDF) membranes. The 
following antibodies were used: rabbit polyclonal antisera against FANCD2 (NB100-
182; Novus Biologicals), FANCI (A301-254A, Bethyl), ATR (ab10312, Abcam), 
ATM (C2C1, Genetech), CHK1 (2345, Cell Signaling), FANCA (ABP-6201, 
Cascade), and pS CDK (9477, Cell Signaling), RPA (NA18, Calbiochem), FLAG 
(F7425, Sigma),and mouse monoclonal sera against α-tubulin (MS-581-PO, 
Neomarkers), cyclin A (SC751, Santa Cruz), CHK1 pS345 (2348, Cell Signaling), 
RPA pS4/8 (A300-245A, Bethyl), and V5 (13202, Cell Signaling).  
 
Immunoprecipitation 
FA-D2 + LacZ, FA-D2 + FANCD2-V5, U2OS, and U2OS 3XFLAG FANCD2 cells 
were lysed in Triton-X lysis buffer (50 mM Tris.HCl pH 7.5, 1% v/v Triton X-100, 
200 mM NaCl, 5mM EDTA, 2mM Na3O4V, Protease inhibitors (Roche), and 0.153g 
B-glycerophosphate) on ice for 15 min followed by sonication for 10 s at 10% 
amplitude using a Fisher Scientific Model 500 Ultrasonic Dismembrator. V5 or 
FLAG-agarose were washed and blocked with NETN100 (20 mM Tris-HCl pH 7.5, 
0.1% NP-40, 100 mM NaCl, 1 mM EDTA, 1 mM Na3O4V, 1 mM NaF, protease 
inhibitor (Roche)) + 1% BSA and the final wash and resuspension was done in Triton-
X lysis buffer. Lysate was then incubated with appropriate agarose at 4°C for 2 h, 
nutating. Beads were then washed in Triton-X lysis buffer and boiled in 1× NuPAGE 
buffer (Invitrogen) and analyzed for the presence of proteins by SDS-PAGE and 
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immunoblotting or stained using Colloidal Blue Staining Kit (Invitrogen) for mass 
spectrometry. 
 
Plasmids, site-directed mutagenesis, and transient transfections  
The full length FANCD2 cDNA sequences were TOPO cloned into the pENTR⁄D-
TOPO (Invitrogen) entry vector, and subsequently recombined into the pLenti6.2/V5-
DEST (Invitrogen) destination vector and used to generate lentivirus for the generation 
of stable cell lines. The TA and TD cDNA were generated by site-directed mutagenesis 
of the wild type FANCD2 cDNA using the Quikchange Site-directed Mutagenesis Kit 
(Stratagene). The forward and reverse oligonucleotide sequences used are as follows: 
TA: S726A-FP 5‟- AGGCCAAAAATTGGTGGCTCCGCTGTGCCTGGC-3‟, 
S624A-FP 5‟- TCCTGCAGTGAGCAGGCTCCTCAGGCCTCTGCAC-3‟, S525A-
FP 5‟- 
CTGGATAACATAGCCCCTCAGCAAATACGAAAACTCTTCTATGTTCTCAGC
AC-3‟; S726A-RP 5‟- GCCAGGCACAGCGGAGCCACCAATTTTTGGCCT-3‟, 
S624A-RP 5‟- GTGCAGAGGCCTGAGGAGCCTGCTCACTGCAGGA-3‟, S525A-
RP 5‟- 
GTGCTGAGAACATAGAAGAGTTTTCGTATTTGCTGAGGGGCTATGTTATCC
AG -3‟. TD: S726D-FP 5‟-AGGCCAAAAATTGGTGGATCCGCTGTGCCTGGC-
3‟, S624D-FP 5‟- TCCTGCAGTGAGCAGGATCCTCAGGCCTCTGCAC-3‟, 
S525D-FP 5‟- 
CTGGATAACATAGACCCTCAGCAAATACGAAAACTCTTCTATGTTCTCAGC
AC-3‟; S726D-RP 5‟-GCCAGGCACAGCGGATCCACCAATTTTTGGCCT-3‟, 
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S624D-RP 5‟- GTGCAGAGGCCTGAGGATCCTGCTCACTGCAGGA-3‟, S525D-
RP 5‟- 
GTGCTGAGAACATAGAAGAGTTTTCGTATTTGCTGAGGGTCTATGTTATCC
AG-3‟. 
 
Lambda phosphatase assay 
Cells were harvested and pellets were split into two, lysed in either lambda 
phosphatase lysis buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.1 mM EGTA, 1 
mM dithiothreitol, 2 mM MnCl2, 0.01% Brij35, 0.5% NP-40, and protease inhibitor) 
or lambda phosphatase buffer with the addition of phosphatase inhibitors, 2 mM 
Na₃VO₄ and 5 mM NaF for 15 min at 4oC followed by sonication for 10 s at 10% 
amplitude using a Fisher Scientific Model 500 Ultrasonic Dismembrator. Whole-cell 
lysates were incubated with or without 30 U of lambda phosphatase pr 10 U of PP1for 
2 h at 30°C, or for the times indicated. Proteins were resolved on NuPage 3-8% w/v 
Tris-Acetate, 4-12% w/v Bis-Tris gels (Invitrogen), or 6% SuperSep Phos-tag (Wako 
Pure Chemical Industries) and transferred to polyvinylidene difluoride (PVDF) 
membranes. Larger proteins were resolved for 5 h on ice. 
 
Cell-cycle synchronization 
HeLa cells or the indicated fibroblast or lymphoblast lines were synchronized by 
double thymidine block method. Cells were treated with 2.5 mM thymidine for 18 
hours, thymidine-free media for 10 hours, and 2.5 mM thymidine for 18 hours to arrest 
the cell cycle at G1/S. Cells were washed twice with phosphate-buffered saline (PBS) 
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and released in DMEM + 12% FBS, L-glutamine, and penicillin/streptomycin and 
analyzed at various time intervals by lambda phosphatase assay and immunoblotting, 
or flow cytometry. For synchronization in M phase, a nocodazole block was used. 
Cells were treated with 0.1 μg/mL nocodazole (Sigma) for 15 hours, and the 
nonadherent cells were collected and washed with PBS, followed by resuspension in 
DMEM without nocodazole and replated in DMEM 12% FBS, L-glutamine, and 
penicillin/streptomycin. 
 
Cell-cycle analysis 
Cells collected from synchronization were resuspended in 0.1 mL PBS and fixed by 
adding 1 mL ice-cold ethanol and stored at -20
o
C until analysis. Cells were then 
washed in PBS and incubated in 0.3-0.5 mL RNase solution (1X RNase) for 10 min at 
37
o
C, then stored on ice. Cells were then incubated on ice for 5-10 min in 50 μg/mL 
propidium iodide (Sigma). DNA content was measured  by BD FACSVerse flow 
cytometer system. 
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APPENDIX I 
Conclusion 
Although FANCD2 is essential for proper function of the FA-BRCA pathway 
and subsequent preservation of chromosome stability, there are many facets 
concerning its regulation, function, and domain architecture that remain elusive to 
date. Thus far, key FANCD2 functions include recruitment of the structure-specific 
endonucleases, SLX4 and FAN1, nucleosome remodeling and assembly, 
transcriptional activation of the tumor suppressor gene TAp63, replisome surveillance 
of chromosomal fragile sites, as well as, resolution of stalled replication forks. 
FANCD2 is an orphan protein, meaning there are no recognizable domains found in 
the protein sequence. Several groups, our lab included, have focused on analyzing the 
domain structure of FANCD2 and have discovered important domains in FANCD2. 
An EDGE motif was found to be essential for ICL-sensitivity [1]. A PIP-motif was 
discovered to be necessary for the interaction between FANCD2 and PCNA and is 
required for efficient FANCD2 monoubiquitination and repair [2]. A CUE ubiquitin 
binding domain in FANCD2 was needed for interaction with FANCI, as well as, 
efficient ICL repair [3]. It was known that FANCD2 functions in the nucleus; 
however, no experiments prior to my graduate research had examined how FANCD2 
is transported for ICL repair. 
 One project that was comprehensively studied during my graduate research, 
focused on the identification and characterization of a putative NLS in the amino 
terminus of FANCD2 [4]. In this research, through initially fusing a predicted NLS 
region to GFP, we discovered that the first 58 amino acids of FANCD2 are required to 
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promote GFP nuclear localization. This region contained two bipartite NLSs, however, 
both were found to be essential for localization. To determine if FANCD2 is 
transported in an importin-α/β manner, treatment with a known inhibitor of this 
pathway, ivermectin, caused GFP localization to be abolished even with the NLS 
fused. In creating FANCD2 truncation mutants, localization and FANCD2 function 
was abrogated without the FANCD2 NLS. FANCD2 was unable to form nuclear foci, 
become monoubiquitinated, or bind to chromatin. Deletion of the NLS also had an 
effect on FANCIs chromatin localization and monoubiquitination, albeit it was not 
abolished, indicating that a subset of FANCI was transported to the nucleus via 
FANCD2. Mutating three highly conserved, positively charged residues, in FANCD2 
caused an intermediate phenotype, suggesting these sites are important for FANCD2s 
localization. Together, these findings suggest that FANCD2 and a subset of FANCI 
are transported to the nucleus through FANCD2s amino terminus NLS and its 
subsequent interaction with importin-α/β. Once in the nucleus, FANCD2 and FANCI 
bind to DNA and are phosphorylated by ATM/ATR, triggering the 
monoubiquitination of FANCD2 and FANCI by the core complex.   
 As mentioned, FANCD2 and FANCI are phosphorylated by ATM/ATR in 
response to DNA damaging agents in order to facilitate the repair of DSBs [5-7]. 
However, it has been demonstrated that FANCD2 is monoubiquitinated during 
unperturbed S phase of the cell cycle and functions to protect stalled replication forks 
from MRE11 degradation [8,9]. FANCD2s DNA damage-independent regulation has 
not been described. Through the utilization of lambda phosphatase assays in my most 
recent project, I found that FANCD2 is extensively phosphorylated, specifically in S 
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phase of the cell cycle. This led us to hypothesize that this is how FANCD2 is being 
regulated in the absence of damage. In synchronizing various cell lines, we found that 
this phosphorylation pattern is independent of the major DNA damage kinases, ATM 
and ATR, as well as the core complex member FANCA. Interestingly, we also showed 
that the ability of FANCD2 to become monoubiquitinated did not alter FANCD2s 
phosphorylation and the monoubiquitinated form of FANCD2 persists even with the 
addition of the phosphatase enzyme. This demonstrates that the DNA damage 
independent phosphorylation of FANCD2 is also independent of its 
monoubiquitination. As this phosphorylation is maximal at S phase, we found that 
FANCD2 is indeed a substrate of CDK phosphorylation. To narrow down which 
residues in FANCD2 could be phosphorylated by CDK, we found several conserved 
SP sites that were surprisingly clustered around FANCD2s site of monoubiquitination. 
These sites were then mutated to phospho-dead alanine (TA) residues or phospho-
mimetic asparagine (TD) residues. Currently, we have found that these sites do alter 
FANCD2s ability to become monoubiquitinated with the addition of MMC or DNA 
replication inhibitors. The TA mutant is constitutively monoubiquitinated and the TD 
mutant does not elicit a response. These preliminary findings suggest that these sites 
are phosphorylated in order to inhibit FANCD2s monoubiquitination. These FANCD2 
mutants need to be further studied to determine the function of FANCD2 
monoubiquitination inhibition. Ultimately, due to the importance of FANCD2 in 
aspects of DNA repair and DNA replication, this protein should be further 
characterized to potentially discover significant therapeutic implications for FA that 
allow for tailored prophylactic and chemotherapeutic measures to be adopted. 
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APPENDIX II 
 
Supplemental information for manuscript II: “Coordinate Nuclear Targeting of the 
FANCD2 and FANCI Proteins via a FANCD2 Nuclear Localization Signal” 
 
Supplemental materials and methods 
Generation of FANCD2-GFP fusion vectors  
To fuse amino acids 1-27 of FANCD2 to the amino terminus of GFP to generate 
D2-1-27-GFP, we PCR amplified the coding sequence of amino acids 1-27 using the 
following forward and reverse primers: FP, 5‟-AAAGAGCTCCACCATGGTTTCC-
3‟; RP, 5‟-TATCTGCAGTGGTTGCTTCCTGGT-3‟. Similarly, D2-24-58-GFP was 
generated by PCR amplifying amino acids 24-55 of FANCD2 using the following 
primers: FP, 5‟-ATAGAGCTCCACCATGAGGAAGCAACCACT-3‟; RP, 5‟-
GGCGCTGCAGAATAATTCCTGATATCTTAAGA-3‟. D2-1-58-GFP was 
generated by PCR amplifying amino acids 1-58 of FANCD2 using the following 
primers: FP, 5‟-AAAGAGCTCCACCATGGTTTCC-3‟; RP 5‟-
CCCCTGCAGAATAATTCCTGATATC-3‟. All amplified fragments were 
directionally cloned into the SacI-PstI site of pGFP-N1 (Clontech). DNA fragments 
were amplified using an Eppendorf Mastercycler ep thermal cycler using the following 
conditions: Thirty cycles of denaturation at 95°C for 30 sec, annealing at 59-65°C for 
1 min, and extension at 68°C for 1 min, followed by cooling to 4°C.  
Supplemental Figures 
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Figure S1. FANCD2 contains a highly conserved amino-terminal nuclear 
localization signal, which facilitates nuclear expression of GFP. (A) cNLS mapper 
(http://nls-mapper.iab.keio.ac.jp/cgi-bin/NLS_Mapper_form.cgi) was used to analyze 
the FANCD2 amino acid sequence for importin /-dependent nuclear localization 
signals (NLSs), and identified amino acids 2-58 as harboring several putative high 
scoring bipartite NLSs (B). (C) D2-1-58-GFP localizes primarily to the nucleus. 
IMR90 cells were transiently transfected with the indicated GFP constructs and 
analyzed by inverted fluorescence microscopy. (D) HeLa cells were transiently 
transfected with wild type GFP (GFP-WT) or GFP fused to amino acids 1-58 of 
FANCD2 (D2-NLS-GFP), incubated in the absence or presence of 25 M ivermectin 
for 20 h, followed by analysis by inverted fluorescence microscopy. (E) The % of 
cells exhibiting both cytoplasmic and nuclear (Cyto. + Nucl.) and exclusive nuclear 
(Nuclear) staining were scored and plotted. Error bars represent the standard errors of 
the means from two independent experiments. ***, p < 0.001. (F) HeLa cells were 
transiently transfected with the indicated GFP constructs and 24 h later cell pellets 
were fractionated into soluble (S) and chromatin (C) fractions. Fractions were resolved 
by SDS-PAGE and immunoblotted with antibodies to GFP, α-tubulin, and H2A. W, 
unfractionated whole-cell extract. (G) The integrated densities of the protein bands 
from Fig. S1F were quantified using ImageJ image processing and analysis software, 
and plotted. While the integrated band densities for a single experiment are shown, 
these experiments were repeated several times with very similar findings. WCE, 
whole-cell extract.
 151 
 
 
 152 
 
 153 
 
 154 
 
Figure S2. The FANCD2 NLS is required for the nuclear localization of a subset 
of FANCI. (A) KEAE FA-D2 hTERT cells or KEAE FA-D2 hTERT cells stably 
expressing FANCD2-WT were incubated in the absence (NT) or presence of MMC 
for 24 h, fixed, stained with rabbit polyclonal anti-FANCD2 or anti-FANCI antibody 
and counterstained with phalloidin and DAPI. AF-488, Alexa Fluor 488. (B) FA-D2 
cells stably expressing FANCD2-WT, FANCD2-∆N57, or FANCD2-∆N100 were 
incubated in the absence (NT) or presence of MMC for 24 h, fixed, stained with 
mouse monoclonal anti-V5 (red) to detect V5-tagged FANCD2 and rabbit polyclonal 
anti-FANCI (green) and counterstained with DAPI (blue). IF microscopy was 
performed with (+ Pre-Perm) and without (No Pre-Perm) a pre-permeabilization step 
(see Materials and Methods). The pre-permeabilization step leads to complete loss of 
fluorescent signal for FANCD2-N57 and FANCD2-N100 because of the high 
solubility of these proteins (see Fig. 2B), while this step is necessary for the resolution 
of FANCI fluorescence signal.
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Figure S3. The FANCD2 NLS is required for efficient FANCI chromatin 
association. FA-D2 cells stably expressing FANCD2-WT (WT), FANCD2-∆N57 
(∆N57), FANCD2-∆N100 (∆N100) or FANCD2-3N (3N) were incubated in the 
absence or presence of MMC for 18 h and cell pellets were fractionated into soluble 
and chromatin-associated fractions (see Figs. 4B and C). The total integrated densities 
of the chromatin-associated (C) nonubiquitinated and monoubiquitinated FANCI 
protein bands were quantified using ImageJ image processing and analysis software, 
and plotted. While the integrated band densities for a single experiment are shown, 
these experiments were repeated several times with similar findings. NT, not treated; 
MMC, MMC-treated.
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Figure S4. The FANCD2 NLS deletion mutants fail to rescue the MMC 
sensitivity of FA-D2 cells. FA-D2 cells stably expressing FANCD2-WT, FANCD2-
K561R, FANCD2-∆N57, FANCD2-∆N100, or FANCD2-3N were treated with the 
indicated concentrations of MMC for 7-10 days. Cells were fixed and stained with 
crystal violet and percent survival calculated and plotted. Each measurement was 
performed in triplicate and experiments were performed multiple times with similar 
results. The 20% trimmed means ( X 20%) for all recorded measurements were 
calculated and plotted. Error bars represent the standard errors of the means. 
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APPENDIX III 
Supplemental information for manuscript III: “Characterization of a Putative CDK 
Phosphorylation Site Cluster in the FANCD2 Protein” 
 
Supplemental Figures 
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Figure S1. FANCD2 phosphorylation is maximal in S phase. U2OS cells were 
synchronized double thymidine block and the cell cycle phase was determined by flow 
cytometric analysis of DNA content. Whole-cell lysates were incubated in the absence 
(-) and presence (+) of lambda phosphatase for 2 h at 30°C and immunoblotted with 
antibodies against FANCD2, FANCI, and Cyclin A. AS, asynchronous whole-cell 
lysate.
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Figure S2. Non-DNA damage inducible phosphorylation of FANCD2 is 
independent of FANCD2 monoubiquitination. HeLa, FA-D2 cells with empty 
plasmid or stably expressing FANCD2-WT, and FANCD2-K561R were incubated 
with lambda phosphatase for 2, 4, 16 h at 30°C and immunoblotted against FANCD2. 
 166 
 
 
 167 
 
Figure S3. FANCD2 is a potential substrate of CDK phosphorylation. U2OS and 
U2OS cells stably expressing 3X FLAG FANCD2-WT were immunoprecipitated with 
anti-FLAG agarose and immune complexes were run on a coomassie gel. 3X FLAG-
FANCD2 bands were then cut out and sent for phospho enrichment and mass 
spectrometry analysis.
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Figure S4. FANCD2 contains a conserved putative CDK consensus site cluster. 
FA-D2 cells stably expressing empty, FANCD2-WT, FANCD2-TA, and FANCD2-
TD were incubated in the absence (-) and presence (+) of 1 μM APH and 1 mM HU 
for 24 h, and whole-cell lysates were immunoblotted with antibodies to FANCD2, V5, 
FANCI, CHK1, CHK1 pS345, RPA, and RPA pS4/8. FANCD2-V5 and FANCI L/S 
ratios were then determined as described.
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